https://trial.medpath.com/news/freya-pharma-launches-phase-ii-study-of-lybrido-for-female-sexual-dysfunction-using-novel-blood-flow-measurement 2025-08-04T17:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/freya-pharma-launches-phase-ii-study-of-lybrido-for-female-sexual-dysfunction-using-novel-blood-flow-measurement 2025-08-04T17:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/transmedics-receives-fda-approval-for-largest-heart-transplant-preservation-trial 2025-08-04T17:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transmedics-receives-fda-approval-for-largest-heart-transplant-preservation-trial 2025-08-04T17:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-inkmune-therapy-meets-primary-endpoints-in-phase-1-2-prostate-cancer-trial 2025-08-04T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-s-inkmune-therapy-meets-primary-endpoints-in-phase-1-2-prostate-cancer-trial 2025-08-04T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/davion-healthcare-files-for-nasdaq-direct-listing-to-advance-non-invasive-medical-technologies 2025-08-04T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/davion-healthcare-files-for-nasdaq-direct-listing-to-advance-non-invasive-medical-technologies 2025-08-04T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-and-helixnano-partner-to-develop-needle-free-heat-stable-mrna-vaccines 2025-08-04T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-and-helixnano-partner-to-develop-needle-free-heat-stable-mrna-vaccines 2025-08-04T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-identify-nod2-gene-variants-as-key-to-enhanced-cancer-immunotherapy-response 2025-08-04T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-identify-nod2-gene-variants-as-key-to-enhanced-cancer-immunotherapy-response 2025-08-04T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/atavistik-bio-doses-first-patient-in-phase-1-trial-of-atv-1601-for-akt1-e17k-mutant-solid-tumors 2025-08-04T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atavistik-bio-doses-first-patient-in-phase-1-trial-of-atv-1601-for-akt1-e17k-mutant-solid-tumors 2025-08-04T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/guy-s-and-st-thomas-nhs-trust-expands-advanced-therapy-manufacturing-capacity-by-60-to-meet-growing-cell-and-gene-therapy-demand 2025-08-04T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guy-s-and-st-thomas-nhs-trust-expands-advanced-therapy-manufacturing-capacity-by-60-to-meet-growing-cell-and-gene-therapy-demand 2025-08-04T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/tildrakizumab-demonstrates-sustained-efficacy-and-safety-in-elderly-psoriasis-patients-over-two-years 2025-08-04T13:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tildrakizumab-demonstrates-sustained-efficacy-and-safety-in-elderly-psoriasis-patients-over-two-years 2025-08-04T13:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/chocolate-compound-theobromine-combined-with-arainosine-outperforms-tamiflu-against-drug-resistant-flu-strains 2025-08-04T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chocolate-compound-theobromine-combined-with-arainosine-outperforms-tamiflu-against-drug-resistant-flu-strains 2025-08-04T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/microbiotica-completes-enrollment-in-phase-1b-trial-of-mb310-for-ulcerative-colitis 2025-08-04T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiotica-completes-enrollment-in-phase-1b-trial-of-mb310-for-ulcerative-colitis 2025-08-04T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/neuroendocrine-tumor-pipeline-shows-strong-growth-with-75-therapies-in-development 2025-08-04T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroendocrine-tumor-pipeline-shows-strong-growth-with-75-therapies-in-development 2025-08-04T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/certara-s-simcyp-simulator-becomes-first-pbpk-modeling-platform-to-receive-ema-qualification-for-eu-regulatory-submissions 2025-08-04T09:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certara-s-simcyp-simulator-becomes-first-pbpk-modeling-platform-to-receive-ema-qualification-for-eu-regulatory-submissions 2025-08-04T09:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/phnyx-lab-secures-4m-to-advance-ai-powered-medical-writing-platform-for-life-sciences 2025-08-04T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phnyx-lab-secures-4m-to-advance-ai-powered-medical-writing-platform-for-life-sciences 2025-08-04T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/raytone-biotech-doses-first-patient-with-novel-tacrolimus-plug-for-dry-eye-disease 2025-08-04T09:26:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raytone-biotech-doses-first-patient-with-novel-tacrolimus-plug-for-dry-eye-disease 2025-08-04T09:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/anbogen-receives-fda-clearance-for-phase-1-2-trial-of-abt-301-triplet-therapy-in-metastatic-colorectal-cancer 2025-08-04T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anbogen-receives-fda-clearance-for-phase-1-2-trial-of-abt-301-triplet-therapy-in-metastatic-colorectal-cancer 2025-08-04T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-to-advance-respiratory-therapeutics-platform 2025-08-04T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-to-advance-respiratory-therapeutics-platform 2025-08-04T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-receives-ind-approval-for-first-in-class-bispecific-adc-jskn022-targeting-pd-l1-and-integrin-avb6 2025-08-04T05:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphamab-oncology-receives-ind-approval-for-first-in-class-bispecific-adc-jskn022-targeting-pd-l1-and-integrin-avb6 2025-08-04T05:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-michigan-develops-at-home-melanoma-detection-patch-using-microneedle-technology 2025-08-04T05:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-michigan-develops-at-home-melanoma-detection-patch-using-microneedle-technology 2025-08-04T05:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/green-space-exposure-during-pregnancy-and-early-childhood-reduces-risk-of-neurodevelopmental-disorders 2025-08-04T05:00:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/green-space-exposure-during-pregnancy-and-early-childhood-reduces-risk-of-neurodevelopmental-disorders 2025-08-04T05:00:13+00:00 hourly 0.9 https://trial.medpath.com/news/dep-sn38-dendrimer-nanoparticle-shows-promise-in-advanced-solid-tumors-with-reduced-toxicity-profile 2025-08-04T01:27:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dep-sn38-dendrimer-nanoparticle-shows-promise-in-advanced-solid-tumors-with-reduced-toxicity-profile 2025-08-04T01:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/australia-develops-world-first-mrna-vaccine-for-foot-and-mouth-disease-in-livestock 2025-08-03T22:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-develops-world-first-mrna-vaccine-for-foot-and-mouth-disease-in-livestock 2025-08-03T22:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/united-imaging-launches-fda-cleared-umr-ultra-3t-mri-system-with-dynamic-motion-visualization-technology 2025-08-03T22:00:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-imaging-launches-fda-cleared-umr-ultra-3t-mri-system-with-dynamic-motion-visualization-technology 2025-08-03T22:00:36+00:00 hourly 0.9 https://trial.medpath.com/news/indian-regulators-scrutinize-biodeal-s-midazolam-nasal-spray-pricing-exemption-amid-nlem-inclusion-controversy 2025-08-03T14:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-regulators-scrutinize-biodeal-s-midazolam-nasal-spray-pricing-exemption-amid-nlem-inclusion-controversy 2025-08-03T14:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-study-of-mrna-2416-shows-promise-in-advanced-solid-tumors-and-ovarian-cancer 2025-08-03T14:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-study-of-mrna-2416-shows-promise-in-advanced-solid-tumors-and-ovarian-cancer 2025-08-03T14:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/luye-pharma-initiates-phase-1-trial-for-novel-triple-target-antidepressant-ly03021 2025-08-03T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luye-pharma-initiates-phase-1-trial-for-novel-triple-target-antidepressant-ly03021 2025-08-03T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-recommends-approval-for-vorasidenib-with-phase-iii-waiver-for-idh-mutant-gliomas-in-india 2025-08-03T09:57:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-recommends-approval-for-vorasidenib-with-phase-iii-waiver-for-idh-mutant-gliomas-in-india 2025-08-03T09:57:15+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-requests-protocol-revisions-for-novartis-itu512-sickle-cell-disease-trial 2025-08-03T09:57:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-requests-protocol-revisions-for-novartis-itu512-sickle-cell-disease-trial 2025-08-03T09:57:11+00:00 hourly 0.9 https://trial.medpath.com/news/lg-group-invests-in-strand-therapeutics-mrna-cancer-platform-through-series-b-funding 2025-08-03T06:03:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lg-group-invests-in-strand-therapeutics-mrna-cancer-platform-through-series-b-funding 2025-08-03T06:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-peritoneal-surface-malignancy-guidelines-address-critical-care-gaps-for-70000-us-patients-annually 2025-08-03T03:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-peritoneal-surface-malignancy-guidelines-address-critical-care-gaps-for-70000-us-patients-annually 2025-08-03T03:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/ice-t-conference-highlights-critical-need-for-standardized-car-t-cell-therapy-supportive-care-protocols 2025-08-03T03:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ice-t-conference-highlights-critical-need-for-standardized-car-t-cell-therapy-supportive-care-protocols 2025-08-03T03:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/indian-clinical-trial-shows-one-third-of-type-2-diabetes-patients-achieve-drug-free-remission 2025-08-03T01:40:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-clinical-trial-shows-one-third-of-type-2-diabetes-patients-achieve-drug-free-remission 2025-08-03T01:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/aptinyx-prepares-for-fda-meeting-on-novel-ptsd-treatment-nyx-783 2025-08-03T01:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptinyx-prepares-for-fda-meeting-on-novel-ptsd-treatment-nyx-783 2025-08-03T01:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/greek-led-clinical-trial-shows-40-reduction-in-death-risk-for-small-cell-lung-cancer-patients 2025-08-02T22:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greek-led-clinical-trial-shows-40-reduction-in-death-risk-for-small-cell-lung-cancer-patients 2025-08-02T22:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-semaglutide-launch-in-canada-faces-regulatory-delay-following-compliance-notice 2025-08-02T18:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-semaglutide-launch-in-canada-faces-regulatory-delay-following-compliance-notice 2025-08-02T18:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/blacksmith-medicines-advances-novel-antibiotic-fg-2101-targeting-drug-resistant-gram-negative-bacteria 2025-08-02T18:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blacksmith-medicines-advances-novel-antibiotic-fg-2101-targeting-drug-resistant-gram-negative-bacteria 2025-08-02T18:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/archimed-acquires-ai-powered-antimicrobial-stewardship-company-arkstone-medical-group 2025-08-02T18:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archimed-acquires-ai-powered-antimicrobial-stewardship-company-arkstone-medical-group 2025-08-02T18:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-nk-cell-therapy-and-chemotherapy-combinations-show-promise-for-pediatric-and-relapsed-aml-treatment 2025-08-02T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-nk-cell-therapy-and-chemotherapy-combinations-show-promise-for-pediatric-and-relapsed-aml-treatment 2025-08-02T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/teodor-trial-launches-to-test-personalized-neoadjuvant-therapy-for-early-stage-breast-cancer 2025-08-02T18:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teodor-trial-launches-to-test-personalized-neoadjuvant-therapy-for-early-stage-breast-cancer 2025-08-02T18:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-secures-200-million-credit-facility-from-orbimed-to-fuel-growth-strategy 2025-08-02T14:11:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-secures-200-million-credit-facility-from-orbimed-to-fuel-growth-strategy 2025-08-02T14:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nanoparticle-formulations-enhance-paclitaxel-delivery-to-cancer-tumors 2025-08-02T14:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nanoparticle-formulations-enhance-paclitaxel-delivery-to-cancer-tumors 2025-08-02T14:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-skyline-trial-shows-promising-results-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-08-02T14:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-skyline-trial-shows-promising-results-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-08-02T14:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/sava-technologies-achieves-10-day-continuous-glucose-monitoring-milestone-with-next-generation-microsensor-platform 2025-08-02T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sava-technologies-achieves-10-day-continuous-glucose-monitoring-milestone-with-next-generation-microsensor-platform 2025-08-02T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-syfovre-data-shows-early-treatment-benefits-and-sustained-safety-in-geographic-atrophy 2025-08-02T10:11:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-syfovre-data-shows-early-treatment-benefits-and-sustained-safety-in-geographic-atrophy 2025-08-02T10:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-strikes-down-fda-s-narrow-interpretation-of-orphan-drug-exclusivity-in-neurelis-v-brenner 2025-08-02T05:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-strikes-down-fda-s-narrow-interpretation-of-orphan-drug-exclusivity-in-neurelis-v-brenner 2025-08-02T05:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-reveals-significant-disparities-in-us-biologics-access-across-immunology-specialties 2025-08-02T03:24:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systematic-review-reveals-significant-disparities-in-us-biologics-access-across-immunology-specialties 2025-08-02T03:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/washington-research-foundation-awards-5-2m-to-launch-collaborative-clinical-trials-program-for-rare-cancer-therapeutics 2025-08-02T02:20:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/washington-research-foundation-awards-5-2m-to-launch-collaborative-clinical-trials-program-for-rare-cancer-therapeutics 2025-08-02T02:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/purgo-scientific-appoints-james-bowman-as-ceo-to-advance-novel-drug-delivery-platform 2025-08-02T02:15:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purgo-scientific-appoints-james-bowman-as-ceo-to-advance-novel-drug-delivery-platform 2025-08-02T02:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-s-imlifidase-enables-gene-therapy-access-for-duchenne-patients-with-pre-existing-antibodies 2025-08-02T02:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-s-imlifidase-enables-gene-therapy-access-for-duchenne-patients-with-pre-existing-antibodies 2025-08-02T02:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-ovarian-cancer-stem-cells-in-preclinical-study 2025-08-01T22:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-ovarian-cancer-stem-cells-in-preclinical-study 2025-08-01T22:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/allan-camaisa-joins-res-nova-biologics-advisory-board-to-advance-breast-cancer-immunotherapy 2025-08-01T22:19:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allan-camaisa-joins-res-nova-biologics-advisory-board-to-advance-breast-cancer-immunotherapy 2025-08-01T22:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/sucralose-artificial-sweetener-reduces-cancer-immunotherapy-effectiveness-through-gut-microbiome-disruption 2025-08-01T22:19:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sucralose-artificial-sweetener-reduces-cancer-immunotherapy-effectiveness-through-gut-microbiome-disruption 2025-08-01T22:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/spine-biopharma-s-sb-01-fails-to-meet-primary-endpoint-in-phase-3-trial-for-chronic-low-back-pain 2025-08-01T22:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spine-biopharma-s-sb-01-fails-to-meet-primary-endpoint-in-phase-3-trial-for-chronic-low-back-pain 2025-08-01T22:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-second-rejection-for-regeneron-s-lymphoma-therapy-odronextamab-due-to-manufacturing-issues 2025-08-01T22:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-second-rejection-for-regeneron-s-lymphoma-therapy-odronextamab-due-to-manufacturing-issues 2025-08-01T22:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-reports-41-revenue-decline-in-q2-2025-launches-1-5-billion-cost-cutting-initiative 2025-08-01T17:22:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-reports-41-revenue-decline-in-q2-2025-launches-1-5-billion-cost-cutting-initiative 2025-08-01T17:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/ozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years 2025-08-01T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years 2025-08-01T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-therapeutics-modifies-alpha3-trial-design-following-patient-death-adopts-standard-lymphodepletion-protocol 2025-08-01T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogene-therapeutics-modifies-alpha3-trial-design-following-patient-death-adopts-standard-lymphodepletion-protocol 2025-08-01T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibody-capture-system-enhances-targeted-mrna-delivery-with-8-fold-improved-binding-efficiency 2025-08-01T17:22:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antibody-capture-system-enhances-targeted-mrna-delivery-with-8-fold-improved-binding-efficiency 2025-08-01T17:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-invests-30-9m-in-i-mab-following-promising-83-response-rate-for-gastric-cancer-bispecific-antibody 2025-08-01T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-invests-30-9m-in-i-mab-following-promising-83-response-rate-for-gastric-cancer-bispecific-antibody 2025-08-01T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-raises-65-million-to-advance-givastomig-phase-2-trial-for-gastric-cancer 2025-08-01T17:19:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-mab-raises-65-million-to-advance-givastomig-phase-2-trial-for-gastric-cancer 2025-08-01T17:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-cdh17-targeting-adc-7mw4911-receives-dual-ind-acceptance-from-fda-and-nmpa 2025-08-01T17:18:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-cdh17-targeting-adc-7mw4911-receives-dual-ind-acceptance-from-fda-and-nmpa 2025-08-01T17:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/esteve-cdmo-acquires-chicago-based-regis-technologies-to-expand-us-manufacturing-capabilities 2025-08-01T17:16:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esteve-cdmo-acquires-chicago-based-regis-technologies-to-expand-us-manufacturing-capabilities 2025-08-01T17:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-secures-2-million-private-placement-to-advance-brain-cancer-and-breast-cancer-drug-development 2025-08-01T17:16:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-secures-2-million-private-placement-to-advance-brain-cancer-and-breast-cancer-drug-development 2025-08-01T17:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-2026-user-fee-rates-for-generic-and-animal-drug-programs-with-inflation-adjustments 2025-08-01T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-2026-user-fee-rates-for-generic-and-animal-drug-programs-with-inflation-adjustments 2025-08-01T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-comprehensive-safety-label-changes-for-all-opioid-pain-medications 2025-08-01T14:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-comprehensive-safety-label-changes-for-all-opioid-pain-medications 2025-08-01T14:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-engages-trump-administration-in-drug-pricing-negotiations-following-strong-q2-performance 2025-08-01T14:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-engages-trump-administration-in-drug-pricing-negotiations-following-strong-q2-performance 2025-08-01T14:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-rights-to-plozasiran-for-395-million-in-greater-china-deal-with-arrowhead 2025-08-01T14:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-acquires-rights-to-plozasiran-for-395-million-in-greater-china-deal-with-arrowhead 2025-08-01T14:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-for-x-scid-reveals-critical-role-of-virtual-memory-t-cells-in-early-human-immunity 2025-08-01T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-for-x-scid-reveals-critical-role-of-virtual-memory-t-cells-in-early-human-immunity 2025-08-01T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/large-real-world-study-questions-effectiveness-of-immunoglobulin-replacement-therapy-in-cll-patients 2025-08-01T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-real-world-study-questions-effectiveness-of-immunoglobulin-replacement-therapy-in-cll-patients 2025-08-01T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/dpiit-and-roche-india-sign-strategic-partnership-to-accelerate-healthcare-innovation-in-critical-therapeutic-areas 2025-08-01T09:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dpiit-and-roche-india-sign-strategic-partnership-to-accelerate-healthcare-innovation-in-critical-therapeutic-areas 2025-08-01T09:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/bd-advances-at-home-hpv-testing-with-ivdr-certification-and-fda-submission-for-cervical-cancer-screening 2025-08-01T05:30:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-advances-at-home-hpv-testing-with-ivdr-certification-and-fda-submission-for-cervical-cancer-screening 2025-08-01T05:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-submits-minjuvi-supplemental-application-for-follicular-lymphoma-in-brazil 2025-08-01T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knight-therapeutics-submits-minjuvi-supplemental-application-for-follicular-lymphoma-in-brazil 2025-08-01T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/certara-appoints-ai-pioneer-dr-chris-bouton-as-cto-to-advance-next-generation-drug-development-platform 2025-08-01T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certara-appoints-ai-pioneer-dr-chris-bouton-as-cto-to-advance-next-generation-drug-development-platform 2025-08-01T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-victoria-and-monash-university-invest-2-25m-in-three-medical-startups-targeting-rare-disease-and-autoimmune-conditions 2025-08-01T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-victoria-and-monash-university-invest-2-25m-in-three-medical-startups-targeting-rare-disease-and-autoimmune-conditions 2025-08-01T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/zenara-pharma-secures-first-generic-sertraline-capsule-approval-with-180-day-market-exclusivity 2025-08-01T05:27:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenara-pharma-secures-first-generic-sertraline-capsule-approval-with-180-day-market-exclusivity 2025-08-01T05:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/chatgpt-reduces-clinical-trial-screening-time-from-40-minutes-to-under-3-minutes-but-human-oversight-still-required 2025-08-01T05:27:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chatgpt-reduces-clinical-trial-screening-time-from-40-minutes-to-under-3-minutes-but-human-oversight-still-required 2025-08-01T05:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/preventive-cardiology-experts-call-for-enhanced-cardiovascular-risk-assessment-and-early-intervention-strategies 2025-08-01T05:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preventive-cardiology-experts-call-for-enhanced-cardiovascular-risk-assessment-and-early-intervention-strategies 2025-08-01T05:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-treatment-de-escalation-advances-through-multi-institutional-clinical-trials 2025-08-01T05:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-treatment-de-escalation-advances-through-multi-institutional-clinical-trials 2025-08-01T05:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/health-system-fragmentation-creates-barriers-to-timely-lung-cancer-biomarker-testing 2025-08-01T03:00:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-system-fragmentation-creates-barriers-to-timely-lung-cancer-biomarker-testing 2025-08-01T03:00:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-vostally-oral-solution-first-liquid-ramipril-formulation-for-hypertension-treatment 2025-08-01T01:40:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-vostally-oral-solution-first-liquid-ramipril-formulation-for-hypertension-treatment 2025-08-01T01:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/maxcyte-partners-with-anocca-to-advance-tcr-t-cell-therapy-manufacturing-using-non-viral-gene-editing-platform 2025-08-01T01:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxcyte-partners-with-anocca-to-advance-tcr-t-cell-therapy-manufacturing-using-non-viral-gene-editing-platform 2025-08-01T01:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/danish-study-confirms-safety-of-jn-1-updated-covid-19-mrna-vaccines-in-real-world-analysis 2025-08-01T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danish-study-confirms-safety-of-jn-1-updated-covid-19-mrna-vaccines-in-real-world-analysis 2025-08-01T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-therapy-reactivates-developmental-gene-to-repair-heart-damage-after-heart-attack 2025-08-01T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-therapy-reactivates-developmental-gene-to-repair-heart-damage-after-heart-attack 2025-08-01T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/radius-pharmaceuticals-secures-patent-victory-for-tymlos-osteoporosis-treatment-through-2038 2025-08-01T01:33:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radius-pharmaceuticals-secures-patent-victory-for-tymlos-osteoporosis-treatment-through-2038 2025-08-01T01:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/genvira-and-labskin-secure-ps1-2-million-uk-canada-grant-for-melanoma-immunotherapy-development 2025-08-01T01:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genvira-and-labskin-secure-ps1-2-million-uk-canada-grant-for-melanoma-immunotherapy-development 2025-08-01T01:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-scientists-achieve-first-in-human-reprogramming-of-stem-cells-to-generate-renewable-cancer-fighting-t-cells 2025-08-01T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-scientists-achieve-first-in-human-reprogramming-of-stem-cells-to-generate-renewable-cancer-fighting-t-cells 2025-08-01T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/immunophotonics-completes-phase-1b-2a-trial-of-ip-001-immunotherapy-for-advanced-solid-tumors 2025-08-01T01:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunophotonics-completes-phase-1b-2a-trial-of-ip-001-immunotherapy-for-advanced-solid-tumors 2025-08-01T01:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondria-targeting-drugs-emerge-as-next-generation-obesity-treatments-to-address-glp-1-limitations 2025-08-01T01:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitochondria-targeting-drugs-emerge-as-next-generation-obesity-treatments-to-address-glp-1-limitations 2025-08-01T01:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-advances-once-weekly-injectable-vmat2-inhibitor-for-tardive-dyskinesia-treatment 2025-08-01T01:30:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-advances-once-weekly-injectable-vmat2-inhibitor-for-tardive-dyskinesia-treatment 2025-08-01T01:30:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2025-08-01T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2025-08-01T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-reports-positive-early-results-from-dual-masked-t-cell-engagers-trials 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-reports-positive-early-results-from-dual-masked-t-cell-engagers-trials 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/benralizumab-shows-promise-in-rare-eosinophilic-disorders-beyond-asthma-study-finds 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benralizumab-shows-promise-in-rare-eosinophilic-disorders-beyond-asthma-study-finds 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ich-opens-public-consultation-on-draft-q3e-guideline-for-extractables-and-leachables-in-drug-products 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ich-opens-public-consultation-on-draft-q3e-guideline-for-extractables-and-leachables-in-drug-products 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-names-charlie-gayer-as-new-ceo-following-jon-stonehouse-s-retirement-announcement 2025-07-31T21:43:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocryst-names-charlie-gayer-as-new-ceo-following-jon-stonehouse-s-retirement-announcement 2025-07-31T21:43:32+00:00 hourly 0.9 https://trial.medpath.com/news/immunitas-therapeutics-unveils-promising-preclinical-data-for-first-in-class-anti-cd161-antibody-imt-380-in-autoimmune-diseases 2025-07-31T21:41:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitas-therapeutics-unveils-promising-preclinical-data-for-first-in-class-anti-cd161-antibody-imt-380-in-autoimmune-diseases 2025-07-31T21:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/duo-trial-reveals-promise-for-durvalumab-olaparib-combination-in-early-stage-endometrial-cancer 2025-07-31T21:35:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duo-trial-reveals-promise-for-durvalumab-olaparib-combination-in-early-stage-endometrial-cancer 2025-07-31T21:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-alzheimer-s-trial-reveals-significant-racial-disparities-in-patient-screening-for-tau-targeting-therapy 2025-07-31T21:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-alzheimer-s-trial-reveals-significant-racial-disparities-in-patient-screening-for-tau-targeting-therapy 2025-07-31T21:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/frazier-healthcare-partners-closes-1-3-billion-fund-for-early-stage-biotech-investments 2025-07-31T21:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frazier-healthcare-partners-closes-1-3-billion-fund-for-early-stage-biotech-investments 2025-07-31T21:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/altasciences-partners-with-voxcell-bioinnovation-to-integrate-3d-bioprinting-technology-into-preclinical-drug-development 2025-07-31T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altasciences-partners-with-voxcell-bioinnovation-to-integrate-3d-bioprinting-technology-into-preclinical-drug-development 2025-07-31T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-precision-medicine-advances-opm-101-melanoma-trial-amid-financial-restructuring 2025-07-31T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncodesign-precision-medicine-advances-opm-101-melanoma-trial-amid-financial-restructuring 2025-07-31T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/protopia-ai-secures-1-25m-air-force-contract-to-advance-privacy-preserving-ai-technology-for-secure-code-development 2025-07-31T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protopia-ai-secures-1-25m-air-force-contract-to-advance-privacy-preserving-ai-technology-for-secure-code-development 2025-07-31T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-immunotherapeutics-advances-sonelokimab-through-phase-3-trials-for-multiple-inflammatory-conditions 2025-07-31T21:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-immunotherapeutics-advances-sonelokimab-through-phase-3-trials-for-multiple-inflammatory-conditions 2025-07-31T21:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-colorado-launches-29-million-effect-trial-to-evaluate-early-fibrinogen-replacement-in-trauma-care 2025-07-31T21:30:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-colorado-launches-29-million-effect-trial-to-evaluate-early-fibrinogen-replacement-in-trauma-care 2025-07-31T21:30:22+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-completes-japanese-enrollment-for-phase-2-harmonic-trial-testing-lp-300-in-never-smoker-lung-cancer-patients 2025-07-31T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-completes-japanese-enrollment-for-phase-2-harmonic-trial-testing-lp-300-in-never-smoker-lung-cancer-patients 2025-07-31T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/immuneonco-s-cd47xcd20-bispecific-imm0306-advances-to-phase-ii-with-promising-efficacy-in-b-cell-lymphomas 2025-07-31T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneonco-s-cd47xcd20-bispecific-imm0306-advances-to-phase-ii-with-promising-efficacy-in-b-cell-lymphomas 2025-07-31T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-strengthens-leadership-with-pfizer-veteran-dolsten-and-oncology-expert-tabernero 2025-07-31T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-therapeutics-strengthens-leadership-with-pfizer-veteran-dolsten-and-oncology-expert-tabernero 2025-07-31T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-secures-five-new-patents-for-il-2-and-il-4-superkine-immunotherapies 2025-07-31T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicenna-secures-five-new-patents-for-il-2-and-il-4-superkine-immunotherapies 2025-07-31T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-announces-10-workforce-reduction-as-part-of-1-5-billion-cost-cutting-initiative 2025-07-31T17:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-announces-10-workforce-reduction-as-part-of-1-5-billion-cost-cutting-initiative 2025-07-31T17:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/chipscreen-biosciences-receives-fda-ind-approval-for-brain-penetrant-aurora-b-inhibitor-cs231295 2025-07-31T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chipscreen-biosciences-receives-fda-ind-approval-for-brain-penetrant-aurora-b-inhibitor-cs231295 2025-07-31T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-reports-strong-q2-2025-results-with-multiple-drug-applications-under-fda-review 2025-07-31T17:30:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-reports-strong-q2-2025-results-with-multiple-drug-applications-under-fda-review 2025-07-31T17:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/symbiosis-pharmaceutical-services-achieves-manufacturing-milestone-with-1000th-sterile-injectable-batch 2025-07-31T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/symbiosis-pharmaceutical-services-achieves-manufacturing-milestone-with-1000th-sterile-injectable-batch 2025-07-31T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-discovers-synergistic-mtor-akt-inhibitor-combination-for-colorectal-cancer-treatment 2025-07-31T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-discovers-synergistic-mtor-akt-inhibitor-combination-for-colorectal-cancer-treatment 2025-07-31T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-rinvoq-achieves-breakthrough-results-in-alopecia-areata-phase-iii-trial 2025-07-31T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-rinvoq-achieves-breakthrough-results-in-alopecia-areata-phase-iii-trial 2025-07-31T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-biktarvy-indication-for-hiv-treatment-experienced-patients-restarting-therapy 2025-07-31T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expanded-biktarvy-indication-for-hiv-treatment-experienced-patients-restarting-therapy 2025-07-31T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/psyence-biomed-partner-psylabs-achieves-gmp-grade-ibogaine-production-milestone 2025-07-31T17:26:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psyence-biomed-partner-psylabs-achieves-gmp-grade-ibogaine-production-milestone 2025-07-31T17:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/china-establishes-initial-pricing-mechanism-for-new-drugs-to-boost-innovation-returns 2025-07-31T17:24:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-establishes-initial-pricing-mechanism-for-new-drugs-to-boost-innovation-returns 2025-07-31T17:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-neuroimmune-modulation-device-for-rheumatoid-arthritis-treatment 2025-07-31T17:24:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-neuroimmune-modulation-device-for-rheumatoid-arthritis-treatment 2025-07-31T17:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-cdmo-eramol-advances-sterile-manufacturing-facility-for-2026-launch 2025-07-31T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-cdmo-eramol-advances-sterile-manufacturing-facility-for-2026-launch 2025-07-31T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-s-sgx945-matches-efficacy-of-fda-approved-therapy-in-behcet-s-disease-phase-2a-trial 2025-07-31T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-s-sgx945-matches-efficacy-of-fda-approved-therapy-in-behcet-s-disease-phase-2a-trial 2025-07-31T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-demonstrates-cardiovascular-benefits-in-type-2-diabetes-patients-with-ascvd-and-osa 2025-07-31T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-demonstrates-cardiovascular-benefits-in-type-2-diabetes-patients-with-ascvd-and-osa 2025-07-31T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/ultromics-secures-55m-series-c-to-scale-ai-powered-heart-failure-diagnostics-across-us-hospitals 2025-07-31T14:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultromics-secures-55m-series-c-to-scale-ai-powered-heart-failure-diagnostics-across-us-hospitals 2025-07-31T14:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-rejects-zydus-phase-iii-clinical-trial-waiver-for-voclosporin-in-lupus-nephritis-treatment 2025-07-31T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-rejects-zydus-phase-iii-clinical-trial-waiver-for-voclosporin-in-lupus-nephritis-treatment 2025-07-31T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-faces-setbacks-in-pain-medicine-development-program 2025-07-31T13:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-faces-setbacks-in-pain-medicine-development-program 2025-07-31T13:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/new-market-report-reveals-global-mycosis-fungoides-clinical-trial-landscape-with-major-pharma-players 2025-07-31T13:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-market-report-reveals-global-mycosis-fungoides-clinical-trial-landscape-with-major-pharma-players 2025-07-31T13:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/aerorx-therapeutics-reports-positive-phase-2a-results-for-first-nebulized-laba-lama-combination-therapy-aero-007-in-copd 2025-07-31T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aerorx-therapeutics-reports-positive-phase-2a-results-for-first-nebulized-laba-lama-combination-therapy-aero-007-in-copd 2025-07-31T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-lead-global-renal-failure-clinical-trials-landscape-in-2025 2025-07-31T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-companies-lead-global-renal-failure-clinical-trials-landscape-in-2025 2025-07-31T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-medical-care-partners-with-azenta-to-advance-precision-kidney-disease-care-through-genomic-analysis 2025-07-31T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-medical-care-partners-with-azenta-to-advance-precision-kidney-disease-care-through-genomic-analysis 2025-07-31T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-vaccine-adjuvant-library-launches-to-accelerate-pandemic-preparedness 2025-07-31T13:30:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-vaccine-adjuvant-library-launches-to-accelerate-pandemic-preparedness 2025-07-31T13:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-receives-ema-prime-designation-for-btk-degrader-bgb-16673-in-waldenstrom-s-macroglobulinemia 2025-07-31T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-receives-ema-prime-designation-for-btk-degrader-bgb-16673-in-waldenstrom-s-macroglobulinemia 2025-07-31T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/flu-associated-brain-swelling-in-children-shows-27-mortality-rate-despite-aggressive-treatment 2025-07-31T10:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flu-associated-brain-swelling-in-children-shows-27-mortality-rate-despite-aggressive-treatment 2025-07-31T10:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/unlv-researchers-achieve-99-pancreas-specific-mrna-delivery-using-novel-endo-nanoparticle-platform 2025-07-31T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unlv-researchers-achieve-99-pancreas-specific-mrna-delivery-using-novel-endo-nanoparticle-platform 2025-07-31T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/touchlight-launches-mbdna-platform-achieving-75-knock-in-rates-in-primary-human-t-cells 2025-07-31T05:24:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/touchlight-launches-mbdna-platform-achieving-75-knock-in-rates-in-primary-human-t-cells 2025-07-31T05:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-experts-convene-to-address-clinical-uncertainties-in-rapidly-evolving-treatment-landscape 2025-07-31T03:00:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-experts-convene-to-address-clinical-uncertainties-in-rapidly-evolving-treatment-landscape 2025-07-31T03:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-safety-management-strategies-transform-pi3k-inhibitor-treatment-delivery-in-metastatic-breast-cancer 2025-07-31T02:58:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-safety-management-strategies-transform-pi3k-inhibitor-treatment-delivery-in-metastatic-breast-cancer 2025-07-31T02:58:18+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-cancer-experts-develop-new-strategies-to-advance-clinical-trials-for-rare-subtypes 2025-07-31T02:58:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kidney-cancer-experts-develop-new-strategies-to-advance-clinical-trials-for-rare-subtypes 2025-07-31T02:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-launches-patent-challenge-against-chinese-military-institute-over-remdesivir-at-unified-patent-court 2025-07-31T01:01:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-launches-patent-challenge-against-chinese-military-institute-over-remdesivir-at-unified-patent-court 2025-07-31T01:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-in-advanced-talks-to-acquire-mental-health-company-gilgamesh-pharmaceuticals-for-1-billion 2025-07-31T00:59:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-in-advanced-talks-to-acquire-mental-health-company-gilgamesh-pharmaceuticals-for-1-billion 2025-07-31T00:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/osteosarcoma-market-poised-for-significant-growth-through-2034-as-novel-therapies-enter-pipeline 2025-07-31T00:59:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osteosarcoma-market-poised-for-significant-growth-through-2034-as-novel-therapies-enter-pipeline 2025-07-31T00:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/inka-health-partners-with-onemednet-to-develop-ai-powered-external-control-arms-for-cancer-drug-development 2025-07-31T00:58:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inka-health-partners-with-onemednet-to-develop-ai-powered-external-control-arms-for-cancer-drug-development 2025-07-31T00:58:36+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-secures-30-million-standby-equity-agreement-to-advance-neurological-and-fibrotic-disease-programs 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-secures-30-million-standby-equity-agreement-to-advance-neurological-and-fibrotic-disease-programs 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-modeyso-as-first-treatment-for-recurrent-h3-k27m-mutant-diffuse-midline-glioma 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-modeyso-as-first-treatment-for-recurrent-h3-k27m-mutant-diffuse-midline-glioma 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/topcon-acquires-ai-powered-diabetic-retinopathy-screening-company-iris-to-expand-connected-care-platform 2025-07-30T21:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topcon-acquires-ai-powered-diabetic-retinopathy-screening-company-iris-to-expand-connected-care-platform 2025-07-30T21:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-to-present-phase-1-data-on-novel-vista-targeting-cancer-therapy-at-esmo-2025 2025-07-30T21:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensei-biotherapeutics-to-present-phase-1-data-on-novel-vista-targeting-cancer-therapy-at-esmo-2025 2025-07-30T21:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/teva-raises-uzedy-revenue-outlook-to-190-200m-as-medincell-s-olanzapine-injectable-advances-toward-fda-filing 2025-07-30T21:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-raises-uzedy-revenue-outlook-to-190-200m-as-medincell-s-olanzapine-injectable-advances-toward-fda-filing 2025-07-30T21:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-loses-patent-term-extension-battle-for-venclexta-cancer-drug-against-uspto 2025-07-30T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-loses-patent-term-extension-battle-for-venclexta-cancer-drug-against-uspto 2025-07-30T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-settles-denosumab-biosimilar-patent-dispute-with-accord-biopharma 2025-07-30T21:30:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-settles-denosumab-biosimilar-patent-dispute-with-accord-biopharma 2025-07-30T21:30:09+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-unveils-next-generation-retinal-surgery-technologies-at-asrs-annual-meeting 2025-07-30T21:29:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcon-unveils-next-generation-retinal-surgery-technologies-at-asrs-annual-meeting 2025-07-30T21:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-repurposing-identifies-four-fda-approved-medications-with-lipid-lowering-effects 2025-07-30T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-drug-repurposing-identifies-four-fda-approved-medications-with-lipid-lowering-effects 2025-07-30T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-revna-biosciences-launch-targeted-egfr-therapy-for-lung-cancer-patients-in-ghana 2025-07-30T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-revna-biosciences-launch-targeted-egfr-therapy-for-lung-cancer-patients-in-ghana 2025-07-30T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-celiac-drug-shows-promise-in-treating-children-with-post-covid-inflammatory-syndrome 2025-07-30T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-celiac-drug-shows-promise-in-treating-children-with-post-covid-inflammatory-syndrome 2025-07-30T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/briapro-files-patent-for-tilsrx-platform-targeting-multiple-cancer-types-with-novel-multivalent-immunotherapy 2025-07-30T17:45:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briapro-files-patent-for-tilsrx-platform-targeting-multiple-cancer-types-with-novel-multivalent-immunotherapy 2025-07-30T17:45:44+00:00 hourly 0.9 https://trial.medpath.com/news/eumentis-therapeutics-receives-fda-clearance-for-phase-2-trial-of-novel-pde10a-inhibitor-em-221-in-schizophrenia 2025-07-30T17:43:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eumentis-therapeutics-receives-fda-clearance-for-phase-2-trial-of-novel-pde10a-inhibitor-em-221-in-schizophrenia 2025-07-30T17:43:57+00:00 hourly 0.9 https://trial.medpath.com/news/actio-biosciences-receives-fda-clearance-and-fast-track-designation-for-first-in-class-kcnt1-epilepsy-treatment 2025-07-30T17:43:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actio-biosciences-receives-fda-clearance-and-fast-track-designation-for-first-in-class-kcnt1-epilepsy-treatment 2025-07-30T17:43:31+00:00 hourly 0.9 https://trial.medpath.com/news/german-federal-patent-court-revokes-key-xarelto-patent-opening-door-for-generic-competition 2025-07-30T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-federal-patent-court-revokes-key-xarelto-patent-opening-door-for-generic-competition 2025-07-30T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/aldevron-establishes-innovation-center-in-boston-biotech-hub-to-accelerate-genomic-medicine-development 2025-07-30T17:41:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aldevron-establishes-innovation-center-in-boston-biotech-hub-to-accelerate-genomic-medicine-development 2025-07-30T17:41:58+00:00 hourly 0.9 https://trial.medpath.com/news/protagenic-therapeutics-secures-japanese-patent-for-modified-stilbenoid-epilepsy-treatment-through-2041 2025-07-30T17:41:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagenic-therapeutics-secures-japanese-patent-for-modified-stilbenoid-epilepsy-treatment-through-2041 2025-07-30T17:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/zuma-7-trial-demonstrates-survival-advantage-for-second-line-car-t-therapy-in-refractory-dlbcl 2025-07-30T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zuma-7-trial-demonstrates-survival-advantage-for-second-line-car-t-therapy-in-refractory-dlbcl 2025-07-30T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-immunotherapies-linked-to-increased-risk-of-liver-cholestasis-global-study-reveals 2025-07-30T17:41:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-immunotherapies-linked-to-increased-risk-of-liver-cholestasis-global-study-reveals 2025-07-30T17:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-tim-3-inhibitor-cobolimab-fails-phase-iii-trial-in-advanced-lung-cancer 2025-07-30T17:40:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-tim-3-inhibitor-cobolimab-fails-phase-iii-trial-in-advanced-lung-cancer 2025-07-30T17:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/vyne-therapeutics-repibresib-gel-fails-to-meet-primary-endpoints-in-phase-2b-vitiligo-trial 2025-07-30T17:39:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyne-therapeutics-repibresib-gel-fails-to-meet-primary-endpoints-in-phase-2b-vitiligo-trial 2025-07-30T17:39:58+00:00 hourly 0.9 https://trial.medpath.com/news/magentiq-eye-secures-series-a-funding-to-advance-ai-powered-colonoscopy-technology 2025-07-30T17:38:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magentiq-eye-secures-series-a-funding-to-advance-ai-powered-colonoscopy-technology 2025-07-30T17:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-gene-therapy-restores-vision-in-patient-with-usher-syndrome-type-1b 2025-07-30T17:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-gene-therapy-restores-vision-in-patient-with-usher-syndrome-type-1b 2025-07-30T17:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/nautilus-biotechnology-partners-with-allen-institute-to-advance-alzheimer-s-research-through-single-molecule-proteomics 2025-07-30T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nautilus-biotechnology-partners-with-allen-institute-to-advance-alzheimer-s-research-through-single-molecule-proteomics 2025-07-30T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-reports-strong-q2-2025-results-raises-guidance-on-tryngolza-success 2025-07-30T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-pharmaceuticals-reports-strong-q2-2025-results-raises-guidance-on-tryngolza-success 2025-07-30T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/cardiosense-receives-fda-clearance-for-cardiotag-first-wearable-to-monitor-heart-rhythm-and-mechanical-function 2025-07-30T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiosense-receives-fda-clearance-for-cardiotag-first-wearable-to-monitor-heart-rhythm-and-mechanical-function 2025-07-30T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/emerald-clinical-trials-appoints-glenn-kerkhof-as-interim-ceo-following-leadership-transition 2025-07-30T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerald-clinical-trials-appoints-glenn-kerkhof-as-interim-ceo-following-leadership-transition 2025-07-30T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-vt3989-for-mesothelioma-treatment 2025-07-30T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-vt3989-for-mesothelioma-treatment 2025-07-30T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/bioduro-and-atombeat-launch-ai-powered-platform-to-accelerate-peptide-drug-discovery 2025-07-30T17:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioduro-and-atombeat-launch-ai-powered-platform-to-accelerate-peptide-drug-discovery 2025-07-30T17:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/prisma-health-and-siemens-healthineers-expand-50m-partnership-to-advance-ai-driven-cancer-care 2025-07-30T13:36:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prisma-health-and-siemens-healthineers-expand-50m-partnership-to-advance-ai-driven-cancer-care 2025-07-30T13:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/dx-vx-secures-220-million-mrna-cancer-vaccine-licensing-deal-with-u-s-biotech-partner 2025-07-30T13:30:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dx-vx-secures-220-million-mrna-cancer-vaccine-licensing-deal-with-u-s-biotech-partner 2025-07-30T13:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-secures-new-zealand-patent-for-hla-matched-whole-cell-cancer-immunotherapy-technology 2025-07-30T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briacell-secures-new-zealand-patent-for-hla-matched-whole-cell-cancer-immunotherapy-technology 2025-07-30T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/anika-s-hyalofast-cartilage-repair-treatment-shows-mixed-results-in-phase-iii-trial 2025-07-30T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anika-s-hyalofast-cartilage-repair-treatment-shows-mixed-results-in-phase-iii-trial 2025-07-30T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-to-present-updated-phase-1a-data-for-fap-targeted-doxorubicin-conjugate-ava6000-at-esmo-2025 2025-07-30T13:29:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-to-present-updated-phase-1a-data-for-fap-targeted-doxorubicin-conjugate-ava6000-at-esmo-2025 2025-07-30T13:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/viridian-therapeutics-secures-385-million-deal-with-kissei-for-thyroid-eye-disease-therapies-in-japan 2025-07-30T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viridian-therapeutics-secures-385-million-deal-with-kissei-for-thyroid-eye-disease-therapies-in-japan 2025-07-30T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-sells-toulouse-biologics-facility-to-sandoz-for-300m-in-strategic-asset-light-transition 2025-07-30T13:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-sells-toulouse-biologics-facility-to-sandoz-for-300m-in-strategic-asset-light-transition 2025-07-30T13:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-analysis-launches-ga-map-mhi-guthealth-diagnostic-kit-for-recurrent-c-difficile-infection 2025-07-30T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-analysis-launches-ga-map-mhi-guthealth-diagnostic-kit-for-recurrent-c-difficile-infection 2025-07-30T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/bioventus-secures-fda-clearance-for-two-next-generation-peripheral-nerve-stimulation-devices 2025-07-30T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioventus-secures-fda-clearance-for-two-next-generation-peripheral-nerve-stimulation-devices 2025-07-30T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-establish-innovation-hubs-in-hyderabad-to-accelerate-drug-development 2025-07-30T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-establish-innovation-hubs-in-hyderabad-to-accelerate-drug-development 2025-07-30T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/nuoyuan-medical-s-pemefolacianine-completes-phase-i-trial-advances-precision-tumor-surgery 2025-07-30T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuoyuan-medical-s-pemefolacianine-completes-phase-i-trial-advances-precision-tumor-surgery 2025-07-30T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/italy-approves-first-gene-therapy-for-hemophilia-b-expanding-access-to-22-new-treatments 2025-07-30T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italy-approves-first-gene-therapy-for-hemophilia-b-expanding-access-to-22-new-treatments 2025-07-30T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-sar446523-receives-fda-orphan-drug-designation-for-relapsed-refractory-multiple-myeloma 2025-07-30T09:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-sar446523-receives-fda-orphan-drug-designation-for-relapsed-refractory-multiple-myeloma 2025-07-30T09:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/mission-barns-secures-first-usda-approval-for-cultivated-pork-fat-launches-commercial-products 2025-07-30T09:27:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-barns-secures-first-usda-approval-for-cultivated-pork-fat-launches-commercial-products 2025-07-30T09:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/esc-congress-2025-to-showcase-pivotal-cardiovascular-trials-with-global-health-impact 2025-07-30T09:27:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esc-congress-2025-to-showcase-pivotal-cardiovascular-trials-with-global-health-impact 2025-07-30T09:27:18+00:00 hourly 0.9 https://trial.medpath.com/news/china-launches-major-trial-testing-nafamostat-mesilate-for-sepsis-treatment-across-32-hospitals 2025-07-30T09:27:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-launches-major-trial-testing-nafamostat-mesilate-for-sepsis-treatment-across-32-hospitals 2025-07-30T09:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-2025-to-showcase-breakthrough-immunotherapy-trials-in-head-and-neck-and-endocrine-cancers 2025-07-30T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-2025-to-showcase-breakthrough-immunotherapy-trials-in-head-and-neck-and-endocrine-cancers 2025-07-30T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/bd-receives-fda-510-k-clearance-for-rapid-point-of-care-covid-19-test 2025-07-30T06:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-receives-fda-510-k-clearance-for-rapid-point-of-care-covid-19-test 2025-07-30T06:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-to-present-phase-ii-data-on-novel-anti-ctla-4-antibody-combination-for-treatment-resistant-colorectal-cancer-at-esmo-2025 2025-07-30T05:24:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-to-present-phase-ii-data-on-novel-anti-ctla-4-antibody-combination-for-treatment-resistant-colorectal-cancer-at-esmo-2025 2025-07-30T05:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-partners-with-toppan-holdings-to-develop-organoid-based-personalized-cancer-treatment-platform 2025-07-30T05:24:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-partners-with-toppan-holdings-to-develop-organoid-based-personalized-cancer-treatment-platform 2025-07-30T05:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-official-dr-vinay-prasad-resigns-after-three-months-amid-sarepta-gene-therapy-controversy 2025-07-30T05:24:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-official-dr-vinay-prasad-resigns-after-three-months-amid-sarepta-gene-therapy-controversy 2025-07-30T05:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-shows-promise-as-dual-vegf-pd-1-inhibitor-in-clear-cell-renal-cell-carcinoma 2025-07-30T05:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivonescimab-shows-promise-as-dual-vegf-pd-1-inhibitor-in-clear-cell-renal-cell-carcinoma 2025-07-30T05:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/cellipont-bioservices-expands-partnership-with-cellvax-for-personalized-gi-cancer-immunotherapy-manufacturing 2025-07-30T01:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellipont-bioservices-expands-partnership-with-cellvax-for-personalized-gi-cancer-immunotherapy-manufacturing 2025-07-30T01:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/leo-cancer-care-s-marie-r-receives-fda-510-k-clearance-for-revolutionary-upright-particle-therapy-platform 2025-07-30T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-cancer-care-s-marie-r-receives-fda-510-k-clearance-for-revolutionary-upright-particle-therapy-platform 2025-07-30T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-kirin-to-present-phase-3-rocatinlimab-results-for-atopic-dermatitis-at-eadv-2025 2025-07-30T01:29:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyowa-kirin-to-present-phase-3-rocatinlimab-results-for-atopic-dermatitis-at-eadv-2025 2025-07-30T01:29:59+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-assay-detects-immunotherapy-response-up-to-5-months-earlier-than-standard-imaging 2025-07-30T01:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-assay-detects-immunotherapy-response-up-to-5-months-earlier-than-standard-imaging 2025-07-30T01:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/3d-printed-catheters-enable-direct-tumor-drug-delivery-for-liver-cancer-treatment 2025-07-30T01:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-printed-catheters-enable-direct-tumor-drug-delivery-for-liver-cancer-treatment 2025-07-30T01:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/diorasis-therapeutics-partners-with-northway-biotech-to-advance-aav-gene-therapy-for-open-angle-glaucoma 2025-07-30T01:27:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diorasis-therapeutics-partners-with-northway-biotech-to-advance-aav-gene-therapy-for-open-angle-glaucoma 2025-07-30T01:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-therapeutics-advances-gaucher-disease-therapy-901-toward-clinical-trials-with-rho-partnership 2025-07-30T01:26:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sharp-therapeutics-advances-gaucher-disease-therapy-901-toward-clinical-trials-with-rho-partnership 2025-07-30T01:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/nota-ai-receives-fast-track-kosdaq-approval-for-ai-optimization-technology-ipo 2025-07-30T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nota-ai-receives-fast-track-kosdaq-approval-for-ai-optimization-technology-ipo 2025-07-30T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-coagadex-for-rare-bleeding-disorder-associated-with-al-amyloidosis 2025-07-30T01:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-coagadex-for-rare-bleeding-disorder-associated-with-al-amyloidosis 2025-07-30T01:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/bionexus-gene-lab-and-fidelion-diagnostics-form-strategic-alliance-to-commercialize-revolutionary-liquid-biopsy-technology-in-southeast-asia 2025-07-30T01:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionexus-gene-lab-and-fidelion-diagnostics-form-strategic-alliance-to-commercialize-revolutionary-liquid-biopsy-technology-in-southeast-asia 2025-07-30T01:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondrial-transplantation-doubles-cisplatin-efficacy-in-advanced-lung-cancer-treatment 2025-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitochondrial-transplantation-doubles-cisplatin-efficacy-in-advanced-lung-cancer-treatment 2025-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-vanzacaftor-tezacaftor-deutivacaftor-for-cystic-fibrosis-treatment-in-england 2025-07-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-vanzacaftor-tezacaftor-deutivacaftor-for-cystic-fibrosis-treatment-in-england 2025-07-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/adc-safety-management-in-mtnbc-genetic-screening-and-prophylactic-strategies-emerge-for-sacituzumab-govitecan 2025-07-29T21:36:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-safety-management-in-mtnbc-genetic-screening-and-prophylactic-strategies-emerge-for-sacituzumab-govitecan 2025-07-29T21:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/ascellahealth-and-abeona-therapeutics-launch-comprehensive-support-program-for-zevaskyn-gene-therapy 2025-07-29T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascellahealth-and-abeona-therapeutics-launch-comprehensive-support-program-for-zevaskyn-gene-therapy 2025-07-29T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/ltz-therapeutics-partners-with-eli-lilly-to-advance-first-in-class-myeloid-engager-platform 2025-07-29T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ltz-therapeutics-partners-with-eli-lilly-to-advance-first-in-class-myeloid-engager-platform 2025-07-29T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-alters-bone-marrow-environment-in-acute-myeloid-leukemia-study-reveals 2025-07-29T21:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-alters-bone-marrow-environment-in-acute-myeloid-leukemia-study-reveals 2025-07-29T21:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-implements-strategic-restructuring-to-advance-nox-a12-and-nox-e36-development 2025-07-29T21:30:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tme-pharma-implements-strategic-restructuring-to-advance-nox-a12-and-nox-e36-development 2025-07-29T21:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/ccr-researchers-develop-water-stable-chemical-warhead-to-enhance-cancer-drug-performance 2025-07-29T21:30:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ccr-researchers-develop-water-stable-chemical-warhead-to-enhance-cancer-drug-performance 2025-07-29T21:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/therini-bio-initiates-phase-1b-trial-of-novel-anti-fibrin-antibody-thn391-for-alzheimer-s-disease 2025-07-29T21:30:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therini-bio-initiates-phase-1b-trial-of-novel-anti-fibrin-antibody-thn391-for-alzheimer-s-disease 2025-07-29T21:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-advances-long-term-extension-study-of-gsk1070806-for-moderate-to-severe-atopic-dermatitis 2025-07-29T21:29:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-advances-long-term-extension-study-of-gsk1070806-for-moderate-to-severe-atopic-dermatitis 2025-07-29T21:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-comparable-effectiveness-of-four-monoclonal-antibodies-in-severe-asthma-treatment 2025-07-29T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-comparable-effectiveness-of-four-monoclonal-antibodies-in-severe-asthma-treatment 2025-07-29T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/formation-bio-licenses-first-in-class-anti-cd226-monoclonal-antibody-for-autoimmune-diseases 2025-07-29T21:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formation-bio-licenses-first-in-class-anti-cd226-monoclonal-antibody-for-autoimmune-diseases 2025-07-29T21:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-reviews-tecovirimat-following-clinical-trial-data-showing-lack-of-effectiveness-against-mpox 2025-07-29T21:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-reviews-tecovirimat-following-clinical-trial-data-showing-lack-of-effectiveness-against-mpox 2025-07-29T21:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-establishes-new-regulatory-framework-for-uvc-disinfection-systems-in-healthcare 2025-07-29T21:27:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-establishes-new-regulatory-framework-for-uvc-disinfection-systems-in-healthcare 2025-07-29T21:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-agrees-to-3-billion-take-private-deal-with-nordic-capital-and-permira 2025-07-29T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bavarian-nordic-agrees-to-3-billion-take-private-deal-with-nordic-capital-and-permira 2025-07-29T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-investment-downturn-creates-new-opportunities-as-select-vc-firms-raise-major-funds 2025-07-29T21:27:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-investment-downturn-creates-new-opportunities-as-select-vc-firms-raise-major-funds 2025-07-29T21:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-edited-cish-knockout-til-therapy-shows-promise-in-metastatic-gastrointestinal-cancers 2025-07-29T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-edited-cish-knockout-til-therapy-shows-promise-in-metastatic-gastrointestinal-cancers 2025-07-29T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-drug-affordability-board-flags-two-diabetes-medications-as-cost-challenges 2025-07-29T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-drug-affordability-board-flags-two-diabetes-medications-as-cost-challenges 2025-07-29T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-launches-phase-3-trial-for-novel-antifungal-fosmanogepix-in-invasive-mold-infections 2025-07-29T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-launches-phase-3-trial-for-novel-antifungal-fosmanogepix-in-invasive-mold-infections 2025-07-29T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/rintatolimod-durvalumab-combination-shows-promise-in-metastatic-pancreatic-cancer-phase-2-trial 2025-07-29T17:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rintatolimod-durvalumab-combination-shows-promise-in-metastatic-pancreatic-cancer-phase-2-trial 2025-07-29T17:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/exonate-advances-exn407-eye-drop-to-phase-iib-trial-for-diabetic-retinopathy-treatment 2025-07-29T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exonate-advances-exn407-eye-drop-to-phase-iib-trial-for-diabetic-retinopathy-treatment 2025-07-29T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fulcrum-therapeutics-experimental-pill-shows-modest-increases-in-fetal-hemoglobin-for-sickle-cell-disease-treatment 2025-07-29T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulcrum-therapeutics-experimental-pill-shows-modest-increases-in-fetal-hemoglobin-for-sickle-cell-disease-treatment 2025-07-29T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/artbio-raises-132-million-series-b-to-advance-lead-212-radiopharmaceutical-for-prostate-cancer 2025-07-29T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artbio-raises-132-million-series-b-to-advance-lead-212-radiopharmaceutical-for-prostate-cancer 2025-07-29T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/relief-therapeutics-to-merge-with-neurox-in-chf-1-billion-deal-creating-ai-driven-neurotherapeutics-platform 2025-07-29T17:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relief-therapeutics-to-merge-with-neurox-in-chf-1-billion-deal-creating-ai-driven-neurotherapeutics-platform 2025-07-29T17:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/ajax-therapeutics-and-schrodinger-expand-jak-inhibitor-partnership-with-new-target 2025-07-29T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ajax-therapeutics-and-schrodinger-expand-jak-inhibitor-partnership-with-new-target 2025-07-29T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/brain-inspired-supercomputer-deployed-at-leipzig-university-to-accelerate-ai-driven-drug-discovery 2025-07-29T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-inspired-supercomputer-deployed-at-leipzig-university-to-accelerate-ai-driven-drug-discovery 2025-07-29T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-design-platform-achieves-70-success-rate-in-rorgt-inhibitor-discovery 2025-07-29T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-drug-design-platform-achieves-70-success-rate-in-rorgt-inhibitor-discovery 2025-07-29T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/exozymes-achieves-breakthrough-in-nct-production-with-ai-driven-biomanufacturing-platform 2025-07-29T17:29:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exozymes-achieves-breakthrough-in-nct-production-with-ai-driven-biomanufacturing-platform 2025-07-29T17:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/virocell-biologics-partners-with-avencell-therapeutics-to-advance-dual-targeted-allogeneic-car-t-therapy 2025-07-29T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virocell-biologics-partners-with-avencell-therapeutics-to-advance-dual-targeted-allogeneic-car-t-therapy 2025-07-29T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-health-acquires-durect-for-63m-to-advance-breakthrough-alcoholic-hepatitis-treatment 2025-07-29T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-health-acquires-durect-for-63m-to-advance-breakthrough-alcoholic-hepatitis-treatment 2025-07-29T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/centauri-therapeutics-secures-additional-5-1m-from-carb-x-to-advance-novel-antimicrobial-abx-01-to-clinical-trials 2025-07-29T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centauri-therapeutics-secures-additional-5-1m-from-carb-x-to-advance-novel-antimicrobial-abx-01-to-clinical-trials 2025-07-29T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/merck-announces-3-billion-cost-cutting-initiative-to-prepare-for-keytruda-patent-expiration 2025-07-29T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-announces-3-billion-cost-cutting-initiative-to-prepare-for-keytruda-patent-expiration 2025-07-29T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/multibeam-raises-31-million-series-b-to-advance-e-beam-lithography-for-ai-chip-manufacturing 2025-07-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multibeam-raises-31-million-series-b-to-advance-e-beam-lithography-for-ai-chip-manufacturing 2025-07-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-receives-100-million-milestone-payment-for-aro-dm1-myotonic-dystrophy-treatment 2025-07-29T09:27:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-receives-100-million-milestone-payment-for-aro-dm1-myotonic-dystrophy-treatment 2025-07-29T09:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-secures-preferred-bidder-status-for-us-manufacturing-facility-to-navigate-tariff-challenges 2025-07-29T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-secures-preferred-bidder-status-for-us-manufacturing-facility-to-navigate-tariff-challenges 2025-07-29T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/td2-oncology-and-curadh-form-strategic-partnership-to-accelerate-radiopharmaceutical-development-for-solid-tumors 2025-07-29T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/td2-oncology-and-curadh-form-strategic-partnership-to-accelerate-radiopharmaceutical-development-for-solid-tumors 2025-07-29T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/syntara-initiates-first-in-human-trial-of-topical-anti-fibrotic-drug-snt-9465-for-hypertrophic-scars 2025-07-29T05:27:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syntara-initiates-first-in-human-trial-of-topical-anti-fibrotic-drug-snt-9465-for-hypertrophic-scars 2025-07-29T05:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-s-her2-targeting-adc-jskn003-receives-fda-orphan-drug-designation-for-gastric-cancer 2025-07-29T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphamab-oncology-s-her2-targeting-adc-jskn003-receives-fda-orphan-drug-designation-for-gastric-cancer 2025-07-29T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-research-institute-hcor-accelerates-phase-3-immunology-trials-with-oracle-clinical-platform 2025-07-29T05:25:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-research-institute-hcor-accelerates-phase-3-immunology-trials-with-oracle-clinical-platform 2025-07-29T05:25:57+00:00 hourly 0.9 https://trial.medpath.com/news/virax-biolabs-strengthens-board-with-diagnostics-veteran-iain-miller-as-company-advances-immune-profiling-platform 2025-07-29T04:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virax-biolabs-strengthens-board-with-diagnostics-veteran-iain-miller-as-company-advances-immune-profiling-platform 2025-07-29T04:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/fertility-preservation-gains-momentum-in-cancer-care-as-awareness-and-access-improve 2025-07-29T02:59:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fertility-preservation-gains-momentum-in-cancer-care-as-awareness-and-access-improve 2025-07-29T02:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-advances-in-sarcoma-treatment-targeting-the-tumor-microenvironment-and-cancer-testis-antigens 2025-07-29T02:58:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-advances-in-sarcoma-treatment-targeting-the-tumor-microenvironment-and-cancer-testis-antigens 2025-07-29T02:58:02+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-deep-brain-stimulation-shows-promise-for-improving-walking-in-parkinson-s-disease 2025-07-29T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-deep-brain-stimulation-shows-promise-for-improving-walking-in-parkinson-s-disease 2025-07-29T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-bain-capital-launch-300m-immunology-drug-development-venture 2025-07-29T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-bain-capital-launch-300m-immunology-drug-development-venture 2025-07-29T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/immvira-s-engineered-exosomes-for-hair-growth-and-fat-reduction-receive-inci-certification-opening-path-to-global-markets 2025-07-29T01:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immvira-s-engineered-exosomes-for-hair-growth-and-fat-reduction-receive-inci-certification-opening-path-to-global-markets 2025-07-29T01:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-s-genio-system-shows-strong-patient-satisfaction-and-efficacy-in-dream-pivotal-study-publication 2025-07-29T01:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-s-genio-system-shows-strong-patient-satisfaction-and-efficacy-in-dream-pivotal-study-publication 2025-07-29T01:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/torrent-pharmaceuticals-prepares-first-wave-semaglutide-launch-following-patent-expiry 2025-07-29T01:26:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/torrent-pharmaceuticals-prepares-first-wave-semaglutide-launch-following-patent-expiry 2025-07-29T01:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/adaptimmune-sells-tecelra-and-cell-therapy-assets-to-us-worldmeds-for-85-million-amid-financial-crisis 2025-07-29T01:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptimmune-sells-tecelra-and-cell-therapy-assets-to-us-worldmeds-for-85-million-amid-financial-crisis 2025-07-29T01:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/life-biosciences-partners-with-singapore-institute-to-advance-epigenetic-therapies-for-age-related-diseases 2025-07-29T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-biosciences-partners-with-singapore-institute-to-advance-epigenetic-therapies-for-age-related-diseases 2025-07-29T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/verabind-tau-assay-shows-superior-early-detection-capabilities-for-alzheimer-s-disease-in-aaic-2025-studies 2025-07-29T01:25:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verabind-tau-assay-shows-superior-early-detection-capabilities-for-alzheimer-s-disease-in-aaic-2025-studies 2025-07-29T01:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/xvivo-heart-preservation-technology-faces-6-12-month-ce-approval-delay-despite-promising-clinical-results 2025-07-29T01:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xvivo-heart-preservation-technology-faces-6-12-month-ce-approval-delay-despite-promising-clinical-results 2025-07-29T01:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-to-build-fourth-planova-virus-filter-plant-in-japan-with-government-support 2025-07-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asahi-kasei-to-build-fourth-planova-virus-filter-plant-in-japan-with-government-support 2025-07-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gen-pharmaceuticals-reports-positive-phase-1-results-for-novel-alzheimer-s-drug-sul-238 2025-07-28T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gen-pharmaceuticals-reports-positive-phase-1-results-for-novel-alzheimer-s-drug-sul-238 2025-07-28T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/pluristyx-secures-strategic-investment-to-advance-ipsc-technologies-and-gene-edited-cell-lines 2025-07-28T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pluristyx-secures-strategic-investment-to-advance-ipsc-technologies-and-gene-edited-cell-lines 2025-07-28T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-rules-prep-act-cannot-shield-covid-test-swab-manufacturer-from-patent-infringement-claims 2025-07-28T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-rules-prep-act-cannot-shield-covid-test-swab-manufacturer-from-patent-infringement-claims 2025-07-28T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/global-alzheimer-s-platform-foundation-and-genentech-partner-to-enhance-diversity-in-alzheimer-s-clinical-trials 2025-07-28T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-alzheimer-s-platform-foundation-and-genentech-partner-to-enhance-diversity-in-alzheimer-s-clinical-trials 2025-07-28T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-biopharma-raises-5-million-in-public-offering-to-fund-cancer-and-inflammatory-disease-drug-development 2025-07-28T21:28:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-biopharma-raises-5-million-in-public-offering-to-fund-cancer-and-inflammatory-disease-drug-development 2025-07-28T21:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/qualigen-therapeutics-secures-4-5-million-in-series-a-3-preferred-stock-financing-to-advance-cancer-therapeutics-pipeline 2025-07-28T21:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qualigen-therapeutics-secures-4-5-million-in-series-a-3-preferred-stock-financing-to-advance-cancer-therapeutics-pipeline 2025-07-28T21:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-pointer-study-demonstrates-structured-lifestyle-interventions-significantly-improve-cognitive-function-in-at-risk-older-adults 2025-07-28T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-pointer-study-demonstrates-structured-lifestyle-interventions-significantly-improve-cognitive-function-in-at-risk-older-adults 2025-07-28T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-completes-transition-to-pure-play-therapeutics-with-ps2-2m-coris-sale 2025-07-28T17:39:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-completes-transition-to-pure-play-therapeutics-with-ps2-2m-coris-sale 2025-07-28T17:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-s-onc-841-shows-promise-as-first-in-class-alzheimer-s-disease-immunotherapy-in-preclinical-studies 2025-07-28T17:39:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-s-onc-841-shows-promise-as-first-in-class-alzheimer-s-disease-immunotherapy-in-preclinical-studies 2025-07-28T17:39:27+00:00 hourly 0.9 https://trial.medpath.com/news/zetagen-therapeutics-secures-uspto-patents-for-novel-intratumoral-breast-cancer-platform 2025-07-28T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zetagen-therapeutics-secures-uspto-patents-for-novel-intratumoral-breast-cancer-platform 2025-07-28T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/cumulus-neuroscience-validates-at-home-digital-biomarkers-show-greater-sensitivity-than-standard-alzheimer-s-assessment-scale 2025-07-28T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumulus-neuroscience-validates-at-home-digital-biomarkers-show-greater-sensitivity-than-standard-alzheimer-s-assessment-scale 2025-07-28T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/isobio-secures-5-million-series-seed-funding-to-advance-antibody-isotope-conjugates-for-cancer-treatment 2025-07-28T17:36:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isobio-secures-5-million-series-seed-funding-to-advance-antibody-isotope-conjugates-for-cancer-treatment 2025-07-28T17:36:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-glenmark-pharmaceuticals-following-manufacturing-quality-violations 2025-07-28T17:35:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letter-to-glenmark-pharmaceuticals-following-manufacturing-quality-violations 2025-07-28T17:35:47+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-reports-promising-mid-year-results-from-phase-2-pancreatic-cancer-combination-therapy-study 2025-07-28T17:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-reports-promising-mid-year-results-from-phase-2-pancreatic-cancer-combination-therapy-study 2025-07-28T17:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-sb431542-shows-triple-action-antiviral-efficacy-against-covid-19-in-preclinical-studies 2025-07-28T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-drug-sb431542-shows-triple-action-antiviral-efficacy-against-covid-19-in-preclinical-studies 2025-07-28T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/acclaim-trial-completes-enrollment-eight-months-ahead-of-schedule-for-colorectal-liver-metastases-study 2025-07-28T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acclaim-trial-completes-enrollment-eight-months-ahead-of-schedule-for-colorectal-liver-metastases-study 2025-07-28T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/angiodynamics-launches-ambition-btk-trial-for-critical-limb-ischemia-treatment-using-auryon-laser-technology 2025-07-28T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angiodynamics-launches-ambition-btk-trial-for-critical-limb-ischemia-treatment-using-auryon-laser-technology 2025-07-28T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/abelacimab-shows-low-bleeding-rates-in-phase-2-periprocedural-trial-may-simplify-anticoagulation-management 2025-07-28T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abelacimab-shows-low-bleeding-rates-in-phase-2-periprocedural-trial-may-simplify-anticoagulation-management 2025-07-28T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-launches-multi-center-panther-registry-study-to-evaluate-real-world-safety-of-renovocath-device 2025-07-28T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-launches-multi-center-panther-registry-study-to-evaluate-real-world-safety-of-renovocath-device 2025-07-28T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/filgotinib-meets-primary-endpoint-in-phase-3-trial-for-axial-spondyloarthritis 2025-07-28T13:39:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/filgotinib-meets-primary-endpoint-in-phase-3-trial-for-axial-spondyloarthritis 2025-07-28T13:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-secures-nmpa-acceptance-for-zunvyl-alzheimer-s-drug-application 2025-07-28T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-medical-system-secures-nmpa-acceptance-for-zunvyl-alzheimer-s-drug-application 2025-07-28T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-bone-mineral-density-as-primary-endpoint-for-entera-bio-s-oral-osteoporosis-drug-phase-3-trial 2025-07-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-bone-mineral-density-as-primary-endpoint-for-entera-bio-s-oral-osteoporosis-drug-phase-3-trial 2025-07-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/onconic-therapeutics-advances-nesuparib-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-07-28T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onconic-therapeutics-advances-nesuparib-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-07-28T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-weathers-sarepta-partnership-turbulence-as-11-billion-rnai-deal-faces-market-scrutiny 2025-07-28T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-weathers-sarepta-partnership-turbulence-as-11-billion-rnai-deal-faces-market-scrutiny 2025-07-28T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-12-billion-partnership-with-hengrui-for-12-drug-development-portfolio 2025-07-28T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-secures-12-billion-partnership-with-hengrui-for-12-drug-development-portfolio 2025-07-28T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-re-vana-for-1b-extended-release-eye-therapy-development 2025-07-28T13:30:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-partners-with-re-vana-for-1b-extended-release-eye-therapy-development 2025-07-28T13:30:29+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-study-shows-can-fite-s-piclidenoson-restores-function-in-vascular-dementia-model 2025-07-28T13:29:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-study-shows-can-fite-s-piclidenoson-restores-function-in-vascular-dementia-model 2025-07-28T13:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/zilbrysq-market-projected-to-grow-21-64-annually-through-2030-following-fda-approval-for-myasthenia-gravis 2025-07-28T13:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zilbrysq-market-projected-to-grow-21-64-annually-through-2030-following-fda-approval-for-myasthenia-gravis 2025-07-28T13:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-launches-first-to-market-p-tau-205-and-p-tau-212-assays-for-alzheimer-s-disease-research 2025-07-28T13:28:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-launches-first-to-market-p-tau-205-and-p-tau-212-assays-for-alzheimer-s-disease-research 2025-07-28T13:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-receives-fda-clearance-for-zw251-novel-glypican-3-targeted-adc-for-hepatocellular-carcinoma 2025-07-28T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-receives-fda-clearance-for-zw251-novel-glypican-3-targeted-adc-for-hepatocellular-carcinoma 2025-07-28T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/artcline-reaches-100-patient-milestone-in-septic-shock-immune-cell-therapy-trial 2025-07-28T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artcline-reaches-100-patient-milestone-in-septic-shock-immune-cell-therapy-trial 2025-07-28T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/diverse-biotech-secures-patents-for-novel-antibody-cannabinoid-and-antibiotic-cannabinoid-conjugates 2025-07-28T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diverse-biotech-secures-patents-for-novel-antibody-cannabinoid-and-antibiotic-cannabinoid-conjugates 2025-07-28T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-and-bioinvent-to-present-updated-bt-001-oncolytic-virus-data-at-esmo-2025 2025-07-28T09:27:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transgene-and-bioinvent-to-present-updated-bt-001-oncolytic-virus-data-at-esmo-2025 2025-07-28T09:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-demonstrates-superior-efficacy-in-phase-iii-lung-cancer-trials-positioning-for-global-regulatory-approvals 2025-07-28T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivonescimab-demonstrates-superior-efficacy-in-phase-iii-lung-cancer-trials-positioning-for-global-regulatory-approvals 2025-07-28T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/kyan-technologies-ex-vivo-platform-demonstrates-clinical-utility-in-relapsed-refractory-non-hodgkin-lymphoma 2025-07-28T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyan-technologies-ex-vivo-platform-demonstrates-clinical-utility-in-relapsed-refractory-non-hodgkin-lymphoma 2025-07-28T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/robles-bioceutics-partners-with-innovigen-to-scale-production-of-senolytic-enhanced-skincare 2025-07-28T08:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robles-bioceutics-partners-with-innovigen-to-scale-production-of-senolytic-enhanced-skincare 2025-07-28T08:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-rules-against-roche-in-pertuzumab-patent-disclosure-case-clarifies-section-104a-requirements-for-biologics 2025-07-28T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-rules-against-roche-in-pertuzumab-patent-disclosure-case-clarifies-section-104a-requirements-for-biologics 2025-07-28T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/indian-drug-regulator-orders-enhanced-ndma-monitoring-for-ranitidine-amid-cancer-concerns 2025-07-28T05:28:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-drug-regulator-orders-enhanced-ndma-monitoring-for-ranitidine-amid-cancer-concerns 2025-07-28T05:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-12-5-billion-deal-with-hengrui-for-copd-drug-and-11-additional-programs 2025-07-28T05:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-secures-12-5-billion-deal-with-hengrui-for-copd-drug-and-11-additional-programs 2025-07-28T05:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-xpovio-for-second-line-multiple-myeloma-treatment-based-on-phase-iii-bench-trial 2025-07-28T05:27:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-xpovio-for-second-line-multiple-myeloma-treatment-based-on-phase-iii-bench-trial 2025-07-28T05:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/osr-holdings-acquires-korean-non-invasive-glucose-monitoring-pioneer-woori-io 2025-07-28T00:57:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osr-holdings-acquires-korean-non-invasive-glucose-monitoring-pioneer-woori-io 2025-07-28T00:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/cuhk-develops-magnetic-microcatheter-for-precise-treatment-of-acute-ischemic-stroke 2025-07-28T00:57:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuhk-develops-magnetic-microcatheter-for-precise-treatment-of-acute-ischemic-stroke 2025-07-28T00:57:47+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-clinical-trial-for-trontinemab-to-prevent-alzheimer-s-disease 2025-07-27T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-clinical-trial-for-trontinemab-to-prevent-alzheimer-s-disease 2025-07-27T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/combination-cardiovascular-therapies-show-promise-in-slowing-cognitive-decline-and-reducing-dementia-pathology 2025-07-27T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-cardiovascular-therapies-show-promise-in-slowing-cognitive-decline-and-reducing-dementia-pathology 2025-07-27T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/immunoact-achieves-profitability-with-india-s-first-car-t-therapy-treating-over-350-cancer-patients 2025-07-27T21:24:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoact-achieves-profitability-with-india-s-first-car-t-therapy-treating-over-350-cancer-patients 2025-07-27T21:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/colorcon-opens-state-of-the-art-film-coating-manufacturing-facility-in-malaysia-to-strengthen-asia-pacific-supply-chain 2025-07-27T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorcon-opens-state-of-the-art-film-coating-manufacturing-facility-in-malaysia-to-strengthen-asia-pacific-supply-chain 2025-07-27T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/granules-india-ceo-dr-k-v-sitaram-rao-announces-resignation-effective-july-2025 2025-07-27T17:14:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granules-india-ceo-dr-k-v-sitaram-rao-announces-resignation-effective-july-2025 2025-07-27T17:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/caspofungin-trough-concentrations-above-3-58-mg-ml-linked-to-improved-clinical-outcomes-in-retrospective-study 2025-07-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caspofungin-trough-concentrations-above-3-58-mg-ml-linked-to-improved-clinical-outcomes-in-retrospective-study 2025-07-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rigicon-initiates-ausome-study-for-artificial-urinary-sphincter-fda-approval 2025-07-27T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigicon-initiates-ausome-study-for-artificial-urinary-sphincter-fda-approval 2025-07-27T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiota-transplantation-shows-safety-and-tolerability-in-six-month-parkinson-s-disease-pilot-study 2025-07-27T09:23:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-microbiota-transplantation-shows-safety-and-tolerability-in-six-month-parkinson-s-disease-pilot-study 2025-07-27T09:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/bangladesh-pharmaceutical-companies-risk-losing-royalty-free-access-to-15-biologic-drugs-due-to-regulatory-delays 2025-07-27T01:20:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bangladesh-pharmaceutical-companies-risk-losing-royalty-free-access-to-15-biologic-drugs-due-to-regulatory-delays 2025-07-27T01:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/india-maintains-firm-stance-against-patent-evergreening-in-global-trade-negotiations 2025-07-27T01:20:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-maintains-firm-stance-against-patent-evergreening-in-global-trade-negotiations 2025-07-27T01:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapeutic-strategies-show-promise-for-overcoming-immunotherapy-resistant-nsclc 2025-07-27T01:19:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapeutic-strategies-show-promise-for-overcoming-immunotherapy-resistant-nsclc 2025-07-27T01:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/nice-expands-nhs-funding-for-astrazeneca-s-lokelma-to-include-outpatient-care 2025-07-27T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-expands-nhs-funding-for-astrazeneca-s-lokelma-to-include-outpatient-care 2025-07-27T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nppa-committee-identifies-patent-discrepancies-in-intas-clozapine-er-pricing-application 2025-07-26T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nppa-committee-identifies-patent-discrepancies-in-intas-clozapine-er-pricing-application 2025-07-26T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-secures-600000-follow-on-order-for-cancer-diagnostic-component 2025-07-26T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-dna-sciences-secures-600000-follow-on-order-for-cancer-diagnostic-component 2025-07-26T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/ptab-director-denies-amgen-s-ipr-challenges-against-bristol-myers-squibb-s-opdivo-patents-based-on-settled-expectations 2025-07-26T17:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptab-director-denies-amgen-s-ipr-challenges-against-bristol-myers-squibb-s-opdivo-patents-based-on-settled-expectations 2025-07-26T17:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/cytodyn-files-100m-mixed-shelf-offering-to-advance-leronlimab-through-phase-iii-trials 2025-07-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytodyn-files-100m-mixed-shelf-offering-to-advance-leronlimab-through-phase-iii-trials 2025-07-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/indoco-remedies-receives-eu-gmp-certification-for-sterile-manufacturing-facility-in-goa 2025-07-26T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indoco-remedies-receives-eu-gmp-certification-for-sterile-manufacturing-facility-in-goa 2025-07-26T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/menopausal-hormone-therapy-shows-persistent-bone-protection-despite-temporary-risk-increase-after-discontinuation 2025-07-26T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menopausal-hormone-therapy-shows-persistent-bone-protection-despite-temporary-risk-increase-after-discontinuation 2025-07-26T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-cylembio-cancer-vaccine-misses-primary-endpoint-in-phase-3-melanoma-trial 2025-07-26T14:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-s-cylembio-cancer-vaccine-misses-primary-endpoint-in-phase-3-melanoma-trial 2025-07-26T14:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/ghana-receives-africa-s-first-novaseq-x-plus-sequencer-to-address-cancer-care-disparities 2025-07-26T13:26:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ghana-receives-africa-s-first-novaseq-x-plus-sequencer-to-address-cancer-care-disparities 2025-07-26T13:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-b-drug-price-negotiations-may-restrict-patient-access-to-cancer-and-autoimmune-treatments 2025-07-26T09:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-part-b-drug-price-negotiations-may-restrict-patient-access-to-cancer-and-autoimmune-treatments 2025-07-26T09:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/ut-sanofi-partnership-develops-ai-model-to-accelerate-mrna-therapeutic-discovery 2025-07-26T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ut-sanofi-partnership-develops-ai-model-to-accelerate-mrna-therapeutic-discovery 2025-07-26T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-zurzuvae-receives-ema-panel-recommendation-for-postpartum-depression-treatment 2025-07-26T09:25:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-s-zurzuvae-receives-ema-panel-recommendation-for-postpartum-depression-treatment 2025-07-26T09:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/community-oncologist-highlights-persistent-access-barriers-to-targeted-breast-cancer-therapies 2025-07-26T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-oncologist-highlights-persistent-access-barriers-to-targeted-breast-cancer-therapies 2025-07-26T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dental-floss-based-vaccine-delivery-system-shows-promise-against-influenza-in-preclinical-study 2025-07-26T05:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-dental-floss-based-vaccine-delivery-system-shows-promise-against-influenza-in-preclinical-study 2025-07-26T05:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-rejects-roche-s-bid-to-force-zydus-to-disclose-sigrima-manufacturing-process 2025-07-26T05:23:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-rejects-roche-s-bid-to-force-zydus-to-disclose-sigrima-manufacturing-process 2025-07-26T05:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/sen-jam-pharmaceutical-initiates-phase-2-trial-for-first-in-class-hangover-prevention-therapy-sjp-001 2025-07-26T05:23:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sen-jam-pharmaceutical-initiates-phase-2-trial-for-first-in-class-hangover-prevention-therapy-sjp-001 2025-07-26T05:23:22+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-clearside-biomedical-s-xipere-for-uveitic-macular-edema-treatment 2025-07-26T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-clearside-biomedical-s-xipere-for-uveitic-macular-edema-treatment 2025-07-26T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-raises-22-million-in-direct-offering-to-fund-narsoplimab-development-amid-regulatory-review 2025-07-26T05:22:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-raises-22-million-in-direct-offering-to-fund-narsoplimab-development-amid-regulatory-review 2025-07-26T05:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/uva-launches-first-of-its-kind-psilocybin-trial-for-prolonged-grief-disorder 2025-07-26T05:22:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-launches-first-of-its-kind-psilocybin-trial-for-prolonged-grief-disorder 2025-07-26T05:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/multidisciplinary-approach-and-technology-integration-show-promise-for-addressing-hidradenitis-suppurativa-care-disparities 2025-07-26T05:22:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multidisciplinary-approach-and-technology-integration-show-promise-for-addressing-hidradenitis-suppurativa-care-disparities 2025-07-26T05:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-advances-bot-bal-combination-therapy-with-phase-3-battman-trial-launch-for-metastatic-colorectal-cancer 2025-07-26T05:21:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-advances-bot-bal-combination-therapy-with-phase-3-battman-trial-launch-for-metastatic-colorectal-cancer 2025-07-26T05:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/new-jersey-senator-advocates-for-state-led-healthcare-ai-implementation-and-rural-health-investment 2025-07-26T05:21:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-jersey-senator-advocates-for-state-led-healthcare-ai-implementation-and-rural-health-investment 2025-07-26T05:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/france-prepares-major-drug-pricing-reforms-as-ceps-report-due-july-2025 2025-07-26T02:57:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/france-prepares-major-drug-pricing-reforms-as-ceps-report-due-july-2025 2025-07-26T02:57:38+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-genomic-profiling-shows-cost-neutrality-despite-underutilization-in-advanced-cancer-care 2025-07-26T02:57:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-genomic-profiling-shows-cost-neutrality-despite-underutilization-in-advanced-cancer-care 2025-07-26T02:57:25+00:00 hourly 0.9 https://trial.medpath.com/news/early-onset-gastrointestinal-cancers-surge-globally-rising-faster-than-any-other-cancer-type-in-young-adults 2025-07-26T02:57:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-onset-gastrointestinal-cancers-surge-globally-rising-faster-than-any-other-cancer-type-in-young-adults 2025-07-26T02:57:13+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-schizophrenia-cognitive-drug-inidascamine-fails-primary-endpoint-in-phase-2-trial 2025-07-26T01:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-schizophrenia-cognitive-drug-inidascamine-fails-primary-endpoint-in-phase-2-trial 2025-07-26T01:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-upgrades-recall-of-160000-bottles-of-levothyroxine-due-to-subpotent-active-ingredients 2025-07-26T01:01:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-upgrades-recall-of-160000-bottles-of-levothyroxine-due-to-subpotent-active-ingredients 2025-07-26T01:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-for-pcos-treatment-in-early-studies 2025-07-26T01:01:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-promise-for-pcos-treatment-in-early-studies 2025-07-26T01:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/recognify-s-inidascamine-misses-primary-endpoint-in-phase-2b-trial-for-schizophrenia-associated-cognitive-impairment 2025-07-26T00:59:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recognify-s-inidascamine-misses-primary-endpoint-in-phase-2b-trial-for-schizophrenia-associated-cognitive-impairment 2025-07-26T00:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-aqneursa-for-niemann-pick-type-c-disease-treatment 2025-07-26T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-of-aqneursa-for-niemann-pick-type-c-disease-treatment 2025-07-26T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-cabometyx-for-advanced-pancreatic-neuroendocrine-tumors 2025-07-26T00:58:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-cabometyx-for-advanced-pancreatic-neuroendocrine-tumors 2025-07-26T00:58:19+00:00 hourly 0.9 https://trial.medpath.com/news/centanafadine-shows-promise-for-pediatric-and-adolescent-adhd-in-phase-3-trials 2025-07-25T21:22:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centanafadine-shows-promise-for-pediatric-and-adolescent-adhd-in-phase-3-trials 2025-07-25T21:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/seca-trial-challenges-routine-aspirin-cessation-in-chronic-subdural-hematoma-surgery 2025-07-25T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seca-trial-challenges-routine-aspirin-cessation-in-chronic-subdural-hematoma-surgery 2025-07-25T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-opens-cambridge-r-d-facility-focused-on-synthetic-rescue-platform-for-rare-diseases 2025-07-25T21:21:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-opens-cambridge-r-d-facility-focused-on-synthetic-rescue-platform-for-rare-diseases 2025-07-25T21:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-pipeline-analysis-reveals-200-investigational-drugs-for-metastatic-hormone-refractory-prostate-cancer 2025-07-25T21:20:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-pipeline-analysis-reveals-200-investigational-drugs-for-metastatic-hormone-refractory-prostate-cancer 2025-07-25T21:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/naip-breaks-ground-on-state-of-the-art-pharmaceutical-research-centre-in-nigeria-s-anambra-state 2025-07-25T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naip-breaks-ground-on-state-of-the-art-pharmaceutical-research-centre-in-nigeria-s-anambra-state 2025-07-25T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/cilcare-secures-eur50000-grant-for-3d-bioprinted-human-model-to-advance-hearing-loss-drug-development 2025-07-25T21:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cilcare-secures-eur50000-grant-for-3d-bioprinted-human-model-to-advance-hearing-loss-drug-development 2025-07-25T21:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/leveragen-and-propeller-bio-form-strategic-partnership-to-advance-next-generation-antibody-discovery-platform 2025-07-25T21:19:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leveragen-and-propeller-bio-form-strategic-partnership-to-advance-next-generation-antibody-discovery-platform 2025-07-25T21:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-cancer-clinical-trials-advance-with-remote-study-models-and-novel-therapeutics 2025-07-25T21:17:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-cancer-clinical-trials-advance-with-remote-study-models-and-novel-therapeutics 2025-07-25T21:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-show-promise-for-asthma-control-in-obese-patients-beyond-weight-loss-benefits 2025-07-25T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-show-promise-for-asthma-control-in-obese-patients-beyond-weight-loss-benefits 2025-07-25T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/phio-pharmaceuticals-secures-u-s-manufacturing-partnership-for-pd-1-silencing-cancer-therapy-ph-762 2025-07-25T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phio-pharmaceuticals-secures-u-s-manufacturing-partnership-for-pd-1-silencing-cancer-therapy-ph-762 2025-07-25T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/india-uk-free-trade-agreement-raises-concerns-over-access-to-affordable-medicines 2025-07-25T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-uk-free-trade-agreement-raises-concerns-over-access-to-affordable-medicines 2025-07-25T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-complete-response-letters-highlight-growing-cmc-challenges-in-immunotherapy-development 2025-07-25T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-complete-response-letters-highlight-growing-cmc-challenges-in-immunotherapy-development 2025-07-25T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/lyell-immunopharma-secures-100-million-private-placement-to-advance-car-t-cell-therapy-development 2025-07-25T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyell-immunopharma-secures-100-million-private-placement-to-advance-car-t-cell-therapy-development 2025-07-25T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-use-disorder-pipeline-shows-promise-with-novel-therapies-in-development 2025-07-25T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-use-disorder-pipeline-shows-promise-with-novel-therapies-in-development 2025-07-25T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-appoints-astrazeneca-s-cristian-massacesi-as-new-chief-medical-officer 2025-07-25T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-appoints-astrazeneca-s-cristian-massacesi-as-new-chief-medical-officer 2025-07-25T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-vorasidenib-for-idh-mutant-grade-2-glioma 2025-07-25T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-recommend-approval-of-vorasidenib-for-idh-mutant-grade-2-glioma 2025-07-25T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-repatha-faces-safety-scrutiny-as-heroic-study-evaluates-cardiovascular-benefits 2025-07-25T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-repatha-faces-safety-scrutiny-as-heroic-study-evaluates-cardiovascular-benefits 2025-07-25T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/aiims-led-study-demonstrates-equal-efficacy-of-three-two-drug-hypertension-combinations-in-south-asian-patients 2025-07-25T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aiims-led-study-demonstrates-equal-efficacy-of-three-two-drug-hypertension-combinations-in-south-asian-patients 2025-07-25T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-doptelet-for-pediatric-immune-thrombocytopenia-with-new-sprinkle-formulation 2025-07-25T17:23:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-doptelet-for-pediatric-immune-thrombocytopenia-with-new-sprinkle-formulation 2025-07-25T17:23:31+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-greater-benefits-in-higher-bmi-patients-with-heart-failure-and-obesity-summit-trial-analysis-reveals 2025-07-25T13:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-greater-benefits-in-higher-bmi-patients-with-heart-failure-and-obesity-summit-trial-analysis-reveals 2025-07-25T13:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/believer-meats-becomes-first-foreign-company-to-secure-fda-clearance-for-cultivated-chicken 2025-07-25T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/believer-meats-becomes-first-foreign-company-to-secure-fda-clearance-for-cultivated-chicken 2025-07-25T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/kintor-pharma-s-kx-826-hair-loss-treatment-achieves-primary-endpoint-in-phase-ii-trial 2025-07-25T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kintor-pharma-s-kx-826-hair-loss-treatment-achieves-primary-endpoint-in-phase-ii-trial 2025-07-25T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/plant-virus-nanoparticles-show-promise-as-novel-cancer-immunotherapy-in-preclinical-studies 2025-07-25T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plant-virus-nanoparticles-show-promise-as-novel-cancer-immunotherapy-in-preclinical-studies 2025-07-25T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-expanding-novo-nordisk-s-alhemo-for-hemophilia-a-and-b-without-inhibitors 2025-07-25T13:27:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-recommend-expanding-novo-nordisk-s-alhemo-for-hemophilia-a-and-b-without-inhibitors 2025-07-25T13:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/milliporesigma-and-washington-university-strengthen-90-year-partnership-to-accelerate-life-sciences-innovation 2025-07-25T13:27:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milliporesigma-and-washington-university-strengthen-90-year-partnership-to-accelerate-life-sciences-innovation 2025-07-25T13:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-expands-beijing-r-d-center-to-accelerate-oncology-drug-development 2025-07-25T13:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-expands-beijing-r-d-center-to-accelerate-oncology-drug-development 2025-07-25T13:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/adocia-s-ultra-rapid-insulin-biochaperone-lispro-meets-primary-endpoint-in-phase-3-trial-for-type-2-diabetes 2025-07-25T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adocia-s-ultra-rapid-insulin-biochaperone-lispro-meets-primary-endpoint-in-phase-3-trial-for-type-2-diabetes 2025-07-25T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/fermented-stevia-extract-shows-selective-cytotoxicity-against-pancreatic-cancer-cells-in-laboratory-study 2025-07-25T13:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fermented-stevia-extract-shows-selective-cytotoxicity-against-pancreatic-cancer-cells-in-laboratory-study 2025-07-25T13:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/precirix-receives-fda-clearance-to-begin-phase-1-trial-of-cam-fap-ac-225-targeted-alpha-therapy 2025-07-25T13:24:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precirix-receives-fda-clearance-to-begin-phase-1-trial-of-cam-fap-ac-225-targeted-alpha-therapy 2025-07-25T13:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/sumitomo-corporation-partners-with-ai-startup-airato-to-revolutionize-cancer-radiation-therapy-planning 2025-07-25T13:24:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sumitomo-corporation-partners-with-ai-startup-airato-to-revolutionize-cancer-radiation-therapy-planning 2025-07-25T13:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/atrial-fibrillation-pipeline-shows-robust-development-with-15-novel-therapies-from-leading-pharmaceutical-companies 2025-07-25T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrial-fibrillation-pipeline-shows-robust-development-with-15-novel-therapies-from-leading-pharmaceutical-companies 2025-07-25T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-regulatory-approval-advances-pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-for-2025-2026-season 2025-07-25T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-regulatory-approval-advances-pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-for-2025-2026-season 2025-07-25T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-raises-hk-1-57-billion-to-accelerate-ai-mrna-platform-and-pipeline-development 2025-07-25T09:22:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-raises-hk-1-57-billion-to-accelerate-ai-mrna-platform-and-pipeline-development 2025-07-25T09:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-initiates-phase-2-3-gardian3-trial-for-stargardt-disease-gene-therapy 2025-07-25T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-initiates-phase-2-3-gardian3-trial-for-stargardt-disease-gene-therapy 2025-07-25T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-cuts-30-of-workforce-refocuses-on-cardiovascular-gene-therapies 2025-07-25T05:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-cuts-30-of-workforce-refocuses-on-cardiovascular-gene-therapies 2025-07-25T05:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/tga-investigates-15-fold-spike-in-vyvanse-adverse-event-reports-amid-social-media-influence 2025-07-25T05:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tga-investigates-15-fold-spike-in-vyvanse-adverse-event-reports-amid-social-media-influence 2025-07-25T05:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-links-depo-provera-to-doubled-brain-tumor-risk-as-pfizer-faces-over-1200-lawsuits 2025-07-25T05:23:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-links-depo-provera-to-doubled-brain-tumor-risk-as-pfizer-faces-over-1200-lawsuits 2025-07-25T05:23:02+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-raises-189-million-in-hong-kong-ipo-advances-first-in-class-4-1bb-immunotherapy 2025-07-25T05:22:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leads-biolabs-raises-189-million-in-hong-kong-ipo-advances-first-in-class-4-1bb-immunotherapy 2025-07-25T05:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/absci-raises-50-million-to-advance-ai-driven-drug-discovery-platform-and-internal-pipeline 2025-07-25T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/absci-raises-50-million-to-advance-ai-driven-drug-discovery-platform-and-internal-pipeline 2025-07-25T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/epic-trial-shows-immunotherapy-extends-survival-in-advanced-penile-cancer-patients 2025-07-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epic-trial-shows-immunotherapy-extends-survival-in-advanced-penile-cancer-patients 2025-07-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/procept-biorobotics-expands-prostate-cancer-trial-to-outpatient-setting-with-first-asc-procedures 2025-07-25T01:30:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/procept-biorobotics-expands-prostate-cancer-trial-to-outpatient-setting-with-first-asc-procedures 2025-07-25T01:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/magnetically-steerable-drug-delivery-vesicles-show-promise-for-precision-cancer-treatment 2025-07-25T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnetically-steerable-drug-delivery-vesicles-show-promise-for-precision-cancer-treatment 2025-07-25T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-coya-303-demonstrates-anti-inflammatory-effects-in-preclinical-alzheimer-s-model 2025-07-25T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-coya-303-demonstrates-anti-inflammatory-effects-in-preclinical-alzheimer-s-model 2025-07-25T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-advances-multi-platform-pipeline-with-novel-arm-technology-for-autoimmune-diseases 2025-07-25T01:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janux-therapeutics-advances-multi-platform-pipeline-with-novel-arm-technology-for-autoimmune-diseases 2025-07-25T01:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/nextcure-s-anti-siglec-15-antibody-nc605-shows-promise-for-osteogenesis-imperfecta-treatment-in-preclinical-study 2025-07-25T01:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcure-s-anti-siglec-15-antibody-nc605-shows-promise-for-osteogenesis-imperfecta-treatment-in-preclinical-study 2025-07-25T01:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-s-brensocatib-wins-fda-approval-as-first-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-07-25T01:25:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-s-brensocatib-wins-fda-approval-as-first-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-07-25T01:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/pedal-study-demonstrates-prospera-kidney-test-accurately-predicts-long-term-outcomes-after-transplant-rejection 2025-07-25T01:25:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pedal-study-demonstrates-prospera-kidney-test-accurately-predicts-long-term-outcomes-after-transplant-rejection 2025-07-25T01:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/hydroxychloroquine-shows-promise-for-kidney-protection-in-primary-glomerular-disease-and-lupus-nephritis 2025-07-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydroxychloroquine-shows-promise-for-kidney-protection-in-primary-glomerular-disease-and-lupus-nephritis 2025-07-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iran-israel-conflict-disrupts-global-clinical-trial-landscape-as-india-overtakes-iran-in-q2-2025 2025-07-24T21:29:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-israel-conflict-disrupts-global-clinical-trial-landscape-as-india-overtakes-iran-in-q2-2025 2025-07-24T21:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/stevanato-group-secures-eur200-million-financing-to-expand-biologics-manufacturing-capacity 2025-07-24T21:29:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stevanato-group-secures-eur200-million-financing-to-expand-biologics-manufacturing-capacity 2025-07-24T21:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-xmab30819-shows-promise-in-advanced-clear-cell-renal-cell-carcinoma 2025-07-24T21:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-xmab30819-shows-promise-in-advanced-clear-cell-renal-cell-carcinoma 2025-07-24T21:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-initiates-phase-clinical-trial-for-bay3018250-in-deep-vein-thrombosis-treatment 2025-07-24T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-initiates-phase-clinical-trial-for-bay3018250-in-deep-vein-thrombosis-treatment 2025-07-24T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-seeks-japan-pmda-approval-for-cardiamp-cell-therapy-in-heart-failure-treatment 2025-07-24T21:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-seeks-japan-pmda-approval-for-cardiamp-cell-therapy-in-heart-failure-treatment 2025-07-24T21:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/roche-discontinues-obesity-drug-ct-173-from-2-7b-carmot-acquisition-citing-lack-of-competitiveness 2025-07-24T21:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-discontinues-obesity-drug-ct-173-from-2-7b-carmot-acquisition-citing-lack-of-competitiveness 2025-07-24T21:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/gate-bioscience-partners-with-lilly-in-856-million-deal-to-develop-novel-molecular-gate-therapeutics 2025-07-24T21:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gate-bioscience-partners-with-lilly-in-856-million-deal-to-develop-novel-molecular-gate-therapeutics 2025-07-24T21:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/gnt-pharma-advances-first-in-class-dual-action-stroke-therapy-nelonemdaz-to-global-phase-3-trials 2025-07-24T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gnt-pharma-advances-first-in-class-dual-action-stroke-therapy-nelonemdaz-to-global-phase-3-trials 2025-07-24T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/cdx-diagnostics-receives-fda-breakthrough-device-designation-for-ai-powered-wats3d-esophageal-cancer-diagnostic-system 2025-07-24T21:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdx-diagnostics-receives-fda-breakthrough-device-designation-for-ai-powered-wats3d-esophageal-cancer-diagnostic-system 2025-07-24T21:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/tcg-labs-soleil-raises-400m-to-build-single-asset-biotech-startups-for-strategic-partnerships 2025-07-24T21:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tcg-labs-soleil-raises-400m-to-build-single-asset-biotech-startups-for-strategic-partnerships 2025-07-24T21:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/medcomms-experts-acquires-nexgen-healthcare-communications-to-expand-global-medical-communications-platform 2025-07-24T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medcomms-experts-acquires-nexgen-healthcare-communications-to-expand-global-medical-communications-platform 2025-07-24T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-s-pda-002-shows-promise-in-phase-2-trial-for-diabetic-foot-ulcers-with-peripheral-artery-disease 2025-07-24T17:44:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celularity-s-pda-002-shows-promise-in-phase-2-trial-for-diabetic-foot-ulcers-with-peripheral-artery-disease 2025-07-24T17:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-s-kb304-gene-therapy-achieves-100-response-rate-in-phase-1-decollete-wrinkle-trial 2025-07-24T17:41:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-s-kb304-gene-therapy-achieves-100-response-rate-in-phase-1-decollete-wrinkle-trial 2025-07-24T17:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-to-present-phase-2-darovasertib-data-for-uveal-melanoma-at-esmo-2025 2025-07-24T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-to-present-phase-2-darovasertib-data-for-uveal-melanoma-at-esmo-2025 2025-07-24T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/roche-explores-direct-to-consumer-drug-sales-model-to-reduce-us-patient-costs 2025-07-24T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-explores-direct-to-consumer-drug-sales-model-to-reduce-us-patient-costs 2025-07-24T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-advance-novel-treatments-for-androgenetic-alopecia-as-researchers-target-30-year-treatment-gap 2025-07-24T17:41:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-advance-novel-treatments-for-androgenetic-alopecia-as-researchers-target-30-year-treatment-gap 2025-07-24T17:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/sanner-opens-first-u-s-manufacturing-facility-in-north-carolina-expanding-global-cdmo-operations 2025-07-24T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanner-opens-first-u-s-manufacturing-facility-in-north-carolina-expanding-global-cdmo-operations 2025-07-24T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-study-links-glipizide-to-13-higher-cardiovascular-risk-in-type-2-diabetes-patients 2025-07-24T17:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-study-links-glipizide-to-13-higher-cardiovascular-risk-in-type-2-diabetes-patients 2025-07-24T17:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/astra-therapeutics-secures-chf-7-75-million-to-develop-novel-anti-parasitic-drugs-for-veterinary-medicine 2025-07-24T17:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astra-therapeutics-secures-chf-7-75-million-to-develop-novel-anti-parasitic-drugs-for-veterinary-medicine 2025-07-24T17:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-partners-with-matchpoint-therapeutics-in-1-billion-anti-inflammatory-drug-development-deal 2025-07-24T17:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-partners-with-matchpoint-therapeutics-in-1-billion-anti-inflammatory-drug-development-deal 2025-07-24T17:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/biostate-ai-expands-global-precision-medicine-platform-through-strategic-partnerships-in-us-china-and-india 2025-07-24T17:29:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostate-ai-expands-global-precision-medicine-platform-through-strategic-partnerships-in-us-china-and-india 2025-07-24T17:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-shows-ibogaine-dramatically-reduces-ptsd-and-depression-in-veterans-with-traumatic-brain-injury 2025-07-24T17:27:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-shows-ibogaine-dramatically-reduces-ptsd-and-depression-in-veterans-with-traumatic-brain-injury 2025-07-24T17:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-for-flibanserin-expansion-to-postmenopausal-women-with-hsdd 2025-07-24T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-flibanserin-expansion-to-postmenopausal-women-with-hsdd 2025-07-24T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-scientists-develop-shelf-stable-synthetic-blood-for-emergency-medicine 2025-07-24T17:26:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-scientists-develop-shelf-stable-synthetic-blood-for-emergency-medicine 2025-07-24T17:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-insulin-successfully-reaches-memory-centers-in-alzheimer-s-brain-imaging-study 2025-07-24T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-insulin-successfully-reaches-memory-centers-in-alzheimer-s-brain-imaging-study 2025-07-24T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/topical-immunotherapy-shows-promise-for-severe-alopecia-areata-despite-variable-response-rates 2025-07-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topical-immunotherapy-shows-promise-for-severe-alopecia-areata-despite-variable-response-rates 2025-07-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-reports-strong-q2-2025-results-with-jakafi-growth-and-new-drug-approvals 2025-07-24T15:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-reports-strong-q2-2025-results-with-jakafi-growth-and-new-drug-approvals 2025-07-24T15:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivermectin-mass-treatment-reduces-malaria-transmission-by-26-in-landmark-bohemia-trial 2025-07-24T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivermectin-mass-treatment-reduces-malaria-transmission-by-26-in-landmark-bohemia-trial 2025-07-24T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-advances-dual-pipeline-strategy-with-novel-therapeutics-for-neurological-and-metabolic-disorders 2025-07-24T13:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-advances-dual-pipeline-strategy-with-novel-therapeutics-for-neurological-and-metabolic-disorders 2025-07-24T13:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/turbine-partners-with-astrazeneca-to-accelerate-adc-discovery-using-ai-powered-virtual-disease-models 2025-07-24T13:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turbine-partners-with-astrazeneca-to-accelerate-adc-discovery-using-ai-powered-virtual-disease-models 2025-07-24T13:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/kling-bio-partners-with-sanofi-to-develop-next-generation-antiviral-antibodies-using-proprietary-b-cell-platform 2025-07-24T13:26:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kling-bio-partners-with-sanofi-to-develop-next-generation-antiviral-antibodies-using-proprietary-b-cell-platform 2025-07-24T13:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-ai-model-pdgrapher-accelerates-drug-discovery-by-predicting-cellular-disease-reversal 2025-07-24T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-ai-model-pdgrapher-accelerates-drug-discovery-by-predicting-cellular-disease-reversal 2025-07-24T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-nears-completion-of-phase-2-3-als-trial-as-combat-als-study-approaches-full-enrollment 2025-07-24T13:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-nears-completion-of-phase-2-3-als-trial-as-combat-als-study-approaches-full-enrollment 2025-07-24T13:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/annexin-pharmaceuticals-receives-uk-approval-for-phase-2a-study-of-anxv-in-diabetic-retinopathy 2025-07-24T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexin-pharmaceuticals-receives-uk-approval-for-phase-2a-study-of-anxv-in-diabetic-retinopathy 2025-07-24T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/tulsi-therapeutics-achieves-100-liver-regeneration-in-world-s-first-stem-cell-exosome-therapy-trial 2025-07-24T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tulsi-therapeutics-achieves-100-liver-regeneration-in-world-s-first-stem-cell-exosome-therapy-trial 2025-07-24T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsy-drug-pipeline-shows-robust-growth-with-90-therapies-in-development-across-75-companies 2025-07-24T09:23:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epilepsy-drug-pipeline-shows-robust-growth-with-90-therapies-in-development-across-75-companies 2025-07-24T09:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/dna-plasmid-therapy-elenagen-shows-90-success-rate-in-treating-chronic-pain-in-dogs-signals-non-opioid-path-for-human-medicine 2025-07-24T09:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-plasmid-therapy-elenagen-shows-90-success-rate-in-treating-chronic-pain-in-dogs-signals-non-opioid-path-for-human-medicine 2025-07-24T09:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/llama-derived-nanobody-shows-promise-for-schizophrenia-cognitive-symptoms-in-preclinical-study 2025-07-24T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/llama-derived-nanobody-shows-promise-for-schizophrenia-cognitive-symptoms-in-preclinical-study 2025-07-24T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/bridging-radiotherapy-shows-promise-in-reducing-car-t-cell-therapy-toxicity-across-b-cell-lymphoma-and-multiple-myeloma 2025-07-24T05:25:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridging-radiotherapy-shows-promise-in-reducing-car-t-cell-therapy-toxicity-across-b-cell-lymphoma-and-multiple-myeloma 2025-07-24T05:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/aicuris-pritelivir-achieves-superior-efficacy-in-phase-3-trial-for-refractory-hsv-in-immunocompromised-patients 2025-07-24T05:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aicuris-pritelivir-achieves-superior-efficacy-in-phase-3-trial-for-refractory-hsv-in-immunocompromised-patients 2025-07-24T05:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-therapeutics-advances-kras-g12d-inhibitor-qtx3034-to-dose-expansion-phase-following-positive-safety-data 2025-07-24T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanta-therapeutics-advances-kras-g12d-inhibitor-qtx3034-to-dose-expansion-phase-following-positive-safety-data 2025-07-24T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-astellas-successfully-defend-prostate-cancer-drug-patent-against-generic-challenge 2025-07-24T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-astellas-successfully-defend-prostate-cancer-drug-patent-against-generic-challenge 2025-07-24T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/hillhurst-biopharmaceuticals-initiates-phase-2a-trial-of-oral-carbon-monoxide-therapy-for-sickle-cell-disease 2025-07-24T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillhurst-biopharmaceuticals-initiates-phase-2a-trial-of-oral-carbon-monoxide-therapy-for-sickle-cell-disease 2025-07-24T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/australia-s-national-reconstruction-fund-invests-150m-in-brandon-capital-to-retain-biotech-innovation-onshore 2025-07-24T01:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-s-national-reconstruction-fund-invests-150m-in-brandon-capital-to-retain-biotech-innovation-onshore 2025-07-24T01:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-raises-747-5-million-in-public-offering-to-advance-ulcerative-colitis-drug-development 2025-07-24T01:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-raises-747-5-million-in-public-offering-to-advance-ulcerative-colitis-drug-development 2025-07-24T01:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-becomes-first-country-to-enable-point-of-care-manufacturing-for-personalized-therapies 2025-07-23T21:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-becomes-first-country-to-enable-point-of-care-manufacturing-for-personalized-therapies 2025-07-23T21:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/qu-biologics-completes-enrollment-in-phase-2-trial-testing-novel-immunomodulator-for-age-related-immune-decline 2025-07-23T21:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qu-biologics-completes-enrollment-in-phase-2-trial-testing-novel-immunomodulator-for-age-related-immune-decline 2025-07-23T21:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-wins-patent-battle-against-novo-nordisk-over-generic-wegovy 2025-07-23T21:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-wins-patent-battle-against-novo-nordisk-over-generic-wegovy 2025-07-23T21:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-dismisses-whistleblower-patent-fraud-lawsuit-against-valeant-and-salix-over-ulcerative-colitis-drug-apriso 2025-07-23T21:27:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-dismisses-whistleblower-patent-fraud-lawsuit-against-valeant-and-salix-over-ulcerative-colitis-drug-apriso 2025-07-23T21:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/autoantibodies-emerge-as-key-predictors-of-cancer-immunotherapy-response-boosting-effectiveness-up-to-10-fold 2025-07-23T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autoantibodies-emerge-as-key-predictors-of-cancer-immunotherapy-response-boosting-effectiveness-up-to-10-fold 2025-07-23T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-advanced-uronav-system-for-precision-focal-therapy-in-prostate-cancer 2025-07-23T21:27:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-advanced-uronav-system-for-precision-focal-therapy-in-prostate-cancer 2025-07-23T21:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-shows-promise-for-fertility-restoration-in-women-with-ovarian-failure 2025-07-23T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapy-shows-promise-for-fertility-restoration-in-women-with-ovarian-failure 2025-07-23T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-researchers-develop-gene-therapy-to-reactivate-silent-genes-in-rett-syndrome 2025-07-23T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-researchers-develop-gene-therapy-to-reactivate-silent-genes-in-rett-syndrome 2025-07-23T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/legacy-healthcare-s-cinainu-shows-sustained-hair-regrowth-in-pediatric-alopecia-areata-phase-2-3-trial 2025-07-23T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legacy-healthcare-s-cinainu-shows-sustained-hair-regrowth-in-pediatric-alopecia-areata-phase-2-3-trial 2025-07-23T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/atopic-dermatitis-market-poised-for-four-fold-growth-by-2034-driven-by-novel-il-13-inhibitor-approvals 2025-07-23T21:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atopic-dermatitis-market-poised-for-four-fold-growth-by-2034-driven-by-novel-il-13-inhibitor-approvals 2025-07-23T21:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-triples-global-oncology-research-network-expanding-real-world-data-access-across-three-countries 2025-07-23T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-triples-global-oncology-research-network-expanding-real-world-data-access-across-three-countries 2025-07-23T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-chemists-overcome-solubility-issues-in-next-generation-malaria-drug-through-molecular-redesign 2025-07-23T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-chemists-overcome-solubility-issues-in-next-generation-malaria-drug-through-molecular-redesign 2025-07-23T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/ai-guided-drug-lp-284-achieves-complete-response-in-treatment-resistant-lymphoma-patient 2025-07-23T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-guided-drug-lp-284-achieves-complete-response-in-treatment-resistant-lymphoma-patient 2025-07-23T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-anti-tslp-antibody-hbm9378-win378-enters-global-phase-2-trial-for-asthma-treatment 2025-07-23T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-anti-tslp-antibody-hbm9378-win378-enters-global-phase-2-trial-for-asthma-treatment 2025-07-23T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/neuroone-receives-uspto-patent-approval-for-novel-neural-probe-manufacturing-technology 2025-07-23T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroone-receives-uspto-patent-approval-for-novel-neural-probe-manufacturing-technology 2025-07-23T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-secures-key-patent-for-albumin-free-hyaluronidase-formulation-advances-toward-2026-market-authorization 2025-07-23T17:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huonslab-secures-key-patent-for-albumin-free-hyaluronidase-formulation-advances-toward-2026-market-authorization 2025-07-23T17:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-restructures-executive-leadership-with-three-key-appointments-to-drive-growth-in-oncology-and-rare-disease 2025-07-23T17:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-restructures-executive-leadership-with-three-key-appointments-to-drive-growth-in-oncology-and-rare-disease 2025-07-23T17:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/former-poseida-ceo-kristin-yarema-named-to-lead-ikena-inmagene-merger-as-companies-advance-anti-ox40-therapy 2025-07-23T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-poseida-ceo-kristin-yarema-named-to-lead-ikena-inmagene-merger-as-companies-advance-anti-ox40-therapy 2025-07-23T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-partners-with-dndi-to-advance-oral-chagas-disease-treatment-an2-502998 2025-07-23T17:28:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-partners-with-dndi-to-advance-oral-chagas-disease-treatment-an2-502998 2025-07-23T17:28:32+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-data-support-mvasi-biosimilar-as-viable-alternative-for-retinal-disease-treatment 2025-07-23T17:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-data-support-mvasi-biosimilar-as-viable-alternative-for-retinal-disease-treatment 2025-07-23T17:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/epicore-biosystems-secures-1-2m-military-contract-for-smart-hydration-wearables 2025-07-23T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epicore-biosystems-secures-1-2m-military-contract-for-smart-hydration-wearables 2025-07-23T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-unveils-ai-powered-alzheimer-s-platforms-at-aaic-2025 2025-07-23T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-unveils-ai-powered-alzheimer-s-platforms-at-aaic-2025 2025-07-23T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-advances-pd-1-vegf-bispecific-antibody-ai-081-to-phase-2-trial-following-promising-early-efficacy-data 2025-07-23T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-advances-pd-1-vegf-bispecific-antibody-ai-081-to-phase-2-trial-following-promising-early-efficacy-data 2025-07-23T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/radiation-therapy-overcomes-primary-resistance-to-pembrolizumab-in-immunologically-cold-nsclc 2025-07-23T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiation-therapy-overcomes-primary-resistance-to-pembrolizumab-in-immunologically-cold-nsclc 2025-07-23T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/inotrem-s-precision-medicine-strategy-shows-breakthrough-results-for-septic-shock-treatment-with-nangibotide 2025-07-23T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inotrem-s-precision-medicine-strategy-shows-breakthrough-results-for-septic-shock-treatment-with-nangibotide 2025-07-23T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-avidity-s-del-zota-for-duchenne-muscular-dystrophy 2025-07-23T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-avidity-s-del-zota-for-duchenne-muscular-dystrophy 2025-07-23T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-launches-two-major-initiatives-to-accelerate-vaccine-development-and-regulatory-approval-in-disease-outbreaks 2025-07-23T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-launches-two-major-initiatives-to-accelerate-vaccine-development-and-regulatory-approval-in-disease-outbreaks 2025-07-23T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-landscape-for-alopecia-universalis-reveals-growing-research-activity-across-major-pharmaceutical-companies 2025-07-23T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trials-landscape-for-alopecia-universalis-reveals-growing-research-activity-across-major-pharmaceutical-companies 2025-07-23T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/cycle-pharmaceuticals-secures-exclusive-u-s-rights-to-phyrago-novel-dasatinib-formulation-for-leukemia-treatment 2025-07-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cycle-pharmaceuticals-secures-exclusive-u-s-rights-to-phyrago-novel-dasatinib-formulation-for-leukemia-treatment 2025-07-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-hospitals-and-siemens-healthineers-launch-ai-driven-research-collaboration-for-liver-disease-diagnostics-in-india 2025-07-23T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apollo-hospitals-and-siemens-healthineers-launch-ai-driven-research-collaboration-for-liver-disease-diagnostics-in-india 2025-07-23T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-launches-beova-tablets-for-overactive-bladder-treatment-in-thailand 2025-07-23T13:29:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-launches-beova-tablets-for-overactive-bladder-treatment-in-thailand 2025-07-23T13:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-san-diego-receives-clia-certification-to-expand-clinical-testing-capabilities 2025-07-23T13:27:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crown-bioscience-san-diego-receives-clia-certification-to-expand-clinical-testing-capabilities 2025-07-23T13:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/iluvien-shows-mixed-results-in-new-day-trial-for-diabetic-macular-edema-treatment 2025-07-23T13:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iluvien-shows-mixed-results-in-new-day-trial-for-diabetic-macular-edema-treatment 2025-07-23T13:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/c-mic-ii-trial-shows-microcurrent-therapy-significantly-improves-heart-function-in-heart-failure-patients 2025-07-23T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-mic-ii-trial-shows-microcurrent-therapy-significantly-improves-heart-function-in-heart-failure-patients 2025-07-23T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/bd-libertas-wearable-injector-enters-first-pharma-sponsored-clinical-trial-for-complex-biologics-delivery 2025-07-23T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-libertas-wearable-injector-enters-first-pharma-sponsored-clinical-trial-for-complex-biologics-delivery 2025-07-23T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/bio-usawa-and-servaregmp-partner-to-establish-monoclonal-antibody-manufacturing-in-africa 2025-07-23T13:23:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-usawa-and-servaregmp-partner-to-establish-monoclonal-antibody-manufacturing-in-africa 2025-07-23T13:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/dispatch-bio-emerges-with-216m-to-develop-universal-solid-tumor-immunotherapy 2025-07-23T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dispatch-bio-emerges-with-216m-to-develop-universal-solid-tumor-immunotherapy 2025-07-23T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/dapagliflozin-demonstrates-sustained-cardiovascular-benefits-in-long-term-diabetes-study 2025-07-23T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dapagliflozin-demonstrates-sustained-cardiovascular-benefits-in-long-term-diabetes-study 2025-07-23T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/ghana-fda-and-company-deny-coa-72-hiv-clinical-trial-claims-following-media-misinformation 2025-07-23T09:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ghana-fda-and-company-deny-coa-72-hiv-clinical-trial-claims-following-media-misinformation 2025-07-23T09:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/a-forall-launches-direct-commercialization-of-sodium-acetate-injection-to-address-u-s-drug-shortage 2025-07-23T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-forall-launches-direct-commercialization-of-sodium-acetate-injection-to-address-u-s-drug-shortage 2025-07-23T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/csl-behring-s-australian-plasma-facility-wins-global-manufacturing-excellence-award-for-advanced-automation 2025-07-23T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-behring-s-australian-plasma-facility-wins-global-manufacturing-excellence-award-for-advanced-automation 2025-07-23T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-expands-nepexto-biosimilar-to-australian-market-for-autoimmune-disease-treatment 2025-07-23T09:22:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-expands-nepexto-biosimilar-to-australian-market-for-autoimmune-disease-treatment 2025-07-23T09:22:30+00:00 hourly 0.9 https://trial.medpath.com/news/ulonivirine-shows-promise-for-once-weekly-hiv-treatment-despite-early-trial-setback 2025-07-23T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ulonivirine-shows-promise-for-once-weekly-hiv-treatment-despite-early-trial-setback 2025-07-23T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/syntellix-secures-nmpa-approval-for-bioabsorbable-metallic-implants-in-china-unlocking-1-4-billion-patient-market 2025-07-23T09:21:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syntellix-secures-nmpa-approval-for-bioabsorbable-metallic-implants-in-china-unlocking-1-4-billion-patient-market 2025-07-23T09:21:53+00:00 hourly 0.9 https://trial.medpath.com/news/pfas-forever-chemicals-linked-to-31-increased-risk-of-type-2-diabetes 2025-07-23T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfas-forever-chemicals-linked-to-31-increased-risk-of-type-2-diabetes 2025-07-23T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/hesperos-achieves-first-digital-twin-of-human-disease-using-malaria-on-a-chip-platform 2025-07-23T05:21:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hesperos-achieves-first-digital-twin-of-human-disease-using-malaria-on-a-chip-platform 2025-07-23T05:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/american-gene-technologies-reports-sustained-hiv-reservoir-reduction-in-phase-1-trial-of-agt103-t-cell-therapy 2025-07-23T05:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-gene-technologies-reports-sustained-hiv-reservoir-reduction-in-phase-1-trial-of-agt103-t-cell-therapy 2025-07-23T05:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-cancer-research-consortium-advances-novel-combination-therapies-through-multi-institutional-collaboration 2025-07-23T02:57:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kidney-cancer-research-consortium-advances-novel-combination-therapies-through-multi-institutional-collaboration 2025-07-23T02:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-pharma-raises-100m-to-advance-inhaled-pulmonary-fibrosis-therapies 2025-07-23T01:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalyn-pharma-raises-100m-to-advance-inhaled-pulmonary-fibrosis-therapies 2025-07-23T01:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/novel-csf-biomarkers-chit1-and-ddah1-may-predict-aria-risk-in-alzheimer-s-patients-receiving-anti-amyloid-therapies 2025-07-23T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-csf-biomarkers-chit1-and-ddah1-may-predict-aria-risk-in-alzheimer-s-patients-receiving-anti-amyloid-therapies 2025-07-23T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-raises-1-74-million-to-advance-immunology-and-oncology-pipeline 2025-07-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tharimmune-raises-1-74-million-to-advance-immunology-and-oncology-pipeline 2025-07-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-3d-printed-epilepsy-drug-for-feeding-tube-administration 2025-07-22T21:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-3d-printed-epilepsy-drug-for-feeding-tube-administration 2025-07-22T21:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-partners-with-johnson-johnson-to-expand-zilretta-access-for-osteoarthritis-knee-pain 2025-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-partners-with-johnson-johnson-to-expand-zilretta-access-for-osteoarthritis-knee-pain 2025-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-acquires-iteos-therapeutics-for-10-05-per-share-following-tigit-program-failure 2025-07-22T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concentra-biosciences-acquires-iteos-therapeutics-for-10-05-per-share-following-tigit-program-failure 2025-07-22T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-radiation-free-stem-cell-transplant-protocol-for-fanconi-anemia-patients 2025-07-22T21:24:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-develop-radiation-free-stem-cell-transplant-protocol-for-fanconi-anemia-patients 2025-07-22T21:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/stride-immunotherapy-achieves-unprecedented-19-6-five-year-survival-rate-in-advanced-liver-cancer 2025-07-22T21:23:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stride-immunotherapy-achieves-unprecedented-19-6-five-year-survival-rate-in-advanced-liver-cancer 2025-07-22T21:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-daratumumab-formulation-reduces-treatment-time-and-premedication-requirements-in-multiple-myeloma 2025-07-22T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-daratumumab-formulation-reduces-treatment-time-and-premedication-requirements-in-multiple-myeloma 2025-07-22T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-brain-health-and-spruce-biosciences-launch-phase-2-trial-for-precision-depression-treatment 2025-07-22T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmnc-brain-health-and-spruce-biosciences-launch-phase-2-trial-for-precision-depression-treatment 2025-07-22T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/precision-genomic-profiling-reveals-multiple-molecular-diagnoses-in-gaucher-disease-patients-with-atypical-presentations 2025-07-22T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-genomic-profiling-reveals-multiple-molecular-diagnoses-in-gaucher-disease-patients-with-atypical-presentations 2025-07-22T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-adalimumab-biosimilar-ibi303-matches-humira-efficacy-with-superior-cost-benefits-in-ankylosing-spondylitis 2025-07-22T21:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-adalimumab-biosimilar-ibi303-matches-humira-efficacy-with-superior-cost-benefits-in-ankylosing-spondylitis 2025-07-22T21:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-replimune-s-melanoma-drug-amid-evolving-regulatory-standards 2025-07-22T21:21:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-replimune-s-melanoma-drug-amid-evolving-regulatory-standards 2025-07-22T21:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/nanoknife-system-shows-promise-for-prostate-cancer-treatment-in-preserve-trial 2025-07-22T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoknife-system-shows-promise-for-prostate-cancer-treatment-in-preserve-trial 2025-07-22T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/sintx-technologies-submits-fda-510-k-for-silicon-nitride-foot-and-ankle-implants 2025-07-22T21:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sintx-technologies-submits-fda-510-k-for-silicon-nitride-foot-and-ankle-implants 2025-07-22T21:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-achieves-100-fda-inspection-success-rate-with-five-facilities-passing-pre-license-review 2025-07-22T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-achieves-100-fda-inspection-success-rate-with-five-facilities-passing-pre-license-review 2025-07-22T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-appoints-leading-prostate-cancer-expert-dr-oliver-sartor-to-scientific-advisory-board 2025-07-22T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharm-theranostics-appoints-leading-prostate-cancer-expert-dr-oliver-sartor-to-scientific-advisory-board 2025-07-22T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-phase-iii-trials-for-two-novel-cardiovascular-fixed-dose-combinations 2025-07-22T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-phase-iii-trials-for-two-novel-cardiovascular-fixed-dose-combinations 2025-07-22T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-strengthens-board-with-neuroscience-and-finance-veterans-as-bezisterim-advances-through-phase-2-trials 2025-07-22T17:30:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovie-strengthens-board-with-neuroscience-and-finance-veterans-as-bezisterim-advances-through-phase-2-trials 2025-07-22T17:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/cgt-catapult-invests-in-spliceor-s-trans-splicing-gene-therapy-platform-for-liver-cancer 2025-07-22T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgt-catapult-invests-in-spliceor-s-trans-splicing-gene-therapy-platform-for-liver-cancer 2025-07-22T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-receives-gene-therapy-for-ultra-rare-nedamss-disease-in-record-13-month-timeline 2025-07-22T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-receives-gene-therapy-for-ultra-rare-nedamss-disease-in-record-13-month-timeline 2025-07-22T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/ixico-secures-full-data-rights-to-landmark-bio-hermes-002-alzheimer-s-study-through-strategic-gap-partnership 2025-07-22T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ixico-secures-full-data-rights-to-landmark-bio-hermes-002-alzheimer-s-study-through-strategic-gap-partnership 2025-07-22T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-discontinues-rare-pediatric-disease-designation-program-despite-rising-approval-trends 2025-07-22T17:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-discontinues-rare-pediatric-disease-designation-program-despite-rising-approval-trends 2025-07-22T17:26:41+00:00 hourly 0.9